BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24:152-160. [PMID: 22967994 DOI: 10.1093/annonc/mds276] [Cited by in Crossref: 480] [Cited by in F6Publishing: 474] [Article Influence: 48.0] [Reference Citation Analysis]
Number Citing Articles
1 Alipour Z, Sweeney JR, Zhang Q, Yang Z. Neuroendocrine Neoplasms of the Pancreas: Diagnostic Challenges and Practical Approach. Adv Anat Pathol 2022. [PMID: 36136369 DOI: 10.1097/PAP.0000000000000369] [Reference Citation Analysis]
2 Li X, Ma Q, Chang C, Li H, Cao D. First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study. Front Oncol 2022;12:958905. [DOI: 10.3389/fonc.2022.958905] [Reference Citation Analysis]
3 Rosery V, Mika S, Schmid KW, Reis H, Stuschke M, Treckmann J, Markus P, Schumacher B, Albers D, Mende B, Lahner H, Wiesweg M, Schuler M, Siveke JT, Kasper S. Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy. J Cancer Res Clin Oncol 2022. [PMID: 36071236 DOI: 10.1007/s00432-022-04314-5] [Reference Citation Analysis]
4 Yang M, Zeng L, Hou S, Tian B, Jin S, Zhang Y. Surgical Outcomes, Long-Term Survivals and Staging Systems of World Health Organization G3 Pancreatic Neuroendocrine Tumors. JCM 2022;11:5253. [DOI: 10.3390/jcm11185253] [Reference Citation Analysis]
5 Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35980649 DOI: 10.1001/jamaoncol.2022.3395] [Reference Citation Analysis]
6 La Salvia A, Persano I, Parlagreco E, Audisio A, Cani M, Brizzi MP. Pancreatic adenocarcinoma and pancreatic high-grade neuroendocrine carcinoma: two sides of the moon. Med Oncol 2022;39:168. [PMID: 35972607 DOI: 10.1007/s12032-022-01764-2] [Reference Citation Analysis]
7 Cabot RC, Rosenberg ES, Dudzinski DM, Baggett MV, Tran KM, Sgroi DC, Shepard JO, Mcdonald EK, Corpuz T, Baughman AW, Wei NJ, Hahn PF, Casey BW, Zhang ML. Case 23-2022: A 49-Year-Old Man with Hypoglycemia. N Engl J Med 2022;387:356-65. [DOI: 10.1056/nejmcpc2115858] [Reference Citation Analysis]
8 Quan L, Liu Y, Cui W, Wang X, Zhang W, Wang Z, Guo C, Lu C, Hu F, Chen X. The associations between serum high-density lipoprotein cholesterol levels and malignant behavior in pancreatic neuroendocrine neoplasms. Lipids Health Dis 2022;21:58. [PMID: 35842659 DOI: 10.1186/s12944-022-01669-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
10 Longo-Muñoz F, Castellano D, Alexandre J, Chawla SP, Fernández C, Kahatt C, Alfaro V, Siguero M, Zeaiter A, Moreno V, Sanz-García E, Awada A, Santaballa A, Subbiah V. Lurbinectedin in patients with pretreated neuroendocrine tumours: Results from a phase II basket study. Eur J Cancer 2022;172:340-8. [PMID: 35830841 DOI: 10.1016/j.ejca.2022.06.024] [Reference Citation Analysis]
11 Borbon LC, Tran CG, Sherman SK, Ear PH, Chandrasekharan C, Bellizzi AM, Dillon JS, O'Dorisio TM, Howe JR. Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms? Ann Surg Oncol 2022. [PMID: 35802214 DOI: 10.1245/s10434-022-12100-3] [Reference Citation Analysis]
12 Kong ZZ, Zhang L. Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report. World J Clin Cases 2022; 10(18): 6241-6246 [DOI: 10.12998/wjcc.v10.i18.6241] [Reference Citation Analysis]
13 Xu Y, Yan L, Chen T, Hu P, Bai J, Ye T, Long Q, Tang Q. Prognosis of patients with poorly differentiated gastric neuroendocrine neoplasms: a multi-center study in China. Future Oncol 2022. [PMID: 35730464 DOI: 10.2217/fon-2022-0140] [Reference Citation Analysis]
14 Iravani A, Parihar AS, Akhurst T, Hicks RJ. Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00465-3] [Reference Citation Analysis]
15 Luo X, Yang M, Tian B, Liu X, Duan K, Zhang Y. Surgical Outcomes and Prognostic Factors of G3 Pancreatic Neuroendocrine Carcinomas: A Consecutive Analysis Based on Previous Study Results. J Clin Med 2022;11:3176. [PMID: 35683561 DOI: 10.3390/jcm11113176] [Reference Citation Analysis]
16 Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D, Quietzsch D, Grabowski P, Cremer B, Maasberg S, Pape UF, Mueller HH, Gress TM, Rinke A, The Members Of The German Net Registry. Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. Cancers (Basel) 2022;14:2718. [PMID: 35681701 DOI: 10.3390/cancers14112718] [Reference Citation Analysis]
17 Ohmoto A, Fujiwara Y, Horita N, Nakano K, Takahashi S. Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. Discov Onc 2022;13. [DOI: 10.1007/s12672-022-00499-w] [Reference Citation Analysis]
18 Buchholz M, Strotmann J, Majchrzak-stiller B, Hahn S, Peters I, Horn J, Müller T, ö-Umlaut P, Uhl W, Braumann C. New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo. Cancers 2022;14:2685. [DOI: 10.3390/cancers14112685] [Reference Citation Analysis]
19 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Que QY, Zhang LC, Bao JQ, Ling SB, Xu X. Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 397-408 [DOI: 10.4240/wjgs.v14.i5.397] [Reference Citation Analysis]
21 Li MX, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Maithel SK, Zhang XF, Pawlik TM. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. J Surg Oncol 2022. [PMID: 35616186 DOI: 10.1002/jso.26928] [Reference Citation Analysis]
22 Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T. Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. Cancers (Basel) 2022;14:2514. [PMID: 35626118 DOI: 10.3390/cancers14102514] [Reference Citation Analysis]
23 Ma ST, Wang DY, Liu YB, Tan HJ, Ge YY, Chi Y, Zhang BL. Prognostic factors of primary neuroendocrine breast cancer: A population-based study. Cancer Med 2022. [PMID: 35499193 DOI: 10.1002/cam4.4557] [Reference Citation Analysis]
24 Ranallo N, Bocchini M, Menis J, Pilotto S, Severi S, Liverani C, Bongiovanni A. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin. Expert Rev Anticancer Ther 2022. [PMID: 35477310 DOI: 10.1080/14737140.2022.2071703] [Reference Citation Analysis]
25 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Liu C, Bian Y, Meng Y, Liu F, Cao K, Zhang H, Fang X, Li J, Yu J, Feng X, Ma C, Lu J, Xu J, Shao C. Preoperative Prediction of G1 and G2/3 Grades in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors Using Multimodality Imaging. Acad Radiol 2022;29:e49-60. [PMID: 34175209 DOI: 10.1016/j.acra.2021.05.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
27 Holmager P, Langer SW, Kjaer A, Ringholm L, Garbyal RS, Pommergaard HC, Hansen CP, Federspiel B, Andreassen M, Knigge U. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Curr Treat Options Oncol 2022. [PMID: 35362798 DOI: 10.1007/s11864-022-00969-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Celik E, Samanci NS, Derin S, Bedir S, Degerli E, Oruc K, Oztas NS, Alkan G, Senyigit A, Turna ZH. A single center's experience of the extrapulmonary neuroendocrine carcinomas. North Clin Istanb 2022;9:35-40. [PMID: 35340315 DOI: 10.14744/nci.2021.47887] [Reference Citation Analysis]
29 Gerbaudo VH, Latif MA. A Step Forward in PET-Based Quantitation of G3 Neuroendocrine Tumor Aggressiveness - The FDZ Score…. Acad Radiol 2022:S1076-6332(22)00140-4. [PMID: 35365399 DOI: 10.1016/j.acra.2022.03.001] [Reference Citation Analysis]
30 Couvelard A, Cros J. An update on the development of concepts, diagnostic criteria, and challenging issues for neuroendocrine neoplasms across different digestive organs. Virchows Arch 2022. [PMID: 35278097 DOI: 10.1007/s00428-022-03306-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Naheed S, Holden C, Tanno L, Pattini L, Pearce NW, Green B, Jaynes E, Cave J, Ottensmeier CH, Pelosi G. Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. BMJ Open 2022;12:e041961. [PMID: 35241462 DOI: 10.1136/bmjopen-2020-041961] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Simon T, Riemer P, Jarosch A, Detjen K, Di Domenico A, Bormann F, Menne A, Khouja S, Monjé N, Childs LH, Lenze D, Leser U, Rossner F, Morkel M, Blüthgen N, Pavel M, Horst D, Capper D, Marinoni I, Perren A, Mamlouk S, Sers C. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors. Genome Med 2022;14:24. [PMID: 35227293 DOI: 10.1186/s13073-022-01018-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Levy S, Verbeek WH, Eskens FA, van den Berg JG, de Groot DJA, van Leerdam ME, Tesselaar ME. First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial. Ther Adv Med Oncol 2022;14:175883592210770. [DOI: 10.1177/17588359221077088] [Reference Citation Analysis]
35 Merola E, Michielan A, Rozzanigo U, Erini M, Sferrazza S, Marcucci S, Sartori C, Trentin C, de Pretis G, Chierichetti F. Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World J Gastrointest Surg 2022; 14(2): 78-106 [DOI: 10.4240/wjgs.v14.i2.78] [Reference Citation Analysis]
36 Zhu C, Kawachi H, Lu X. A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy. Gastric Cancer 2022. [PMID: 35179666 DOI: 10.1007/s10120-022-01277-x] [Reference Citation Analysis]
37 Nakano M, Shimada Y, Matsumoto Y, Saiki T, Zhou Q, Sasaki K, Moriyama M, Yoshihara K, Natsumeda M, Kuriyama Y, Takii Y, Watanabe G, Umezu H, Okuda S, Ikeuchi T, Wakai T, Saijo Y. Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. Clin J Gastroenterol 2022. [PMID: 35133626 DOI: 10.1007/s12328-022-01599-4] [Reference Citation Analysis]
38 Chen G, Xu Q, Qian S, Wang Z, Wang S. Survival Analysis in Gastrointestinal Neuroendocrine Carcinoma With Bone Metastasis at Diagnosis. Front Surg 2022;9:820725. [DOI: 10.3389/fsurg.2022.820725] [Reference Citation Analysis]
39 Inaba Y, Hijioka S, Iwama I, Asai T, Miyamura H, Chatani S, Hasegawa T, Murata S, Kato M, Sato Y, Yamaura H, Onaya H, Shimizu J, Hara K. Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms. Asia Ocean J Nucl Med Biol. 2022;10:1-13. [PMID: 35083344 DOI: 10.22038/aojnmb.2021.56254.1390] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Bilski M, Mertowska P, Mertowski S, Sawicki M, Hymos A, Niedźwiedzka-Rystwej P, Grywalska E. The Role of Conventionally Fractionated Radiotherapy and Stereotactic Radiotherapy in the Treatment of Carcinoid Tumors and Large-Cell Neuroendocrine Cancer of the Lung. Cancers (Basel) 2021;14:177. [PMID: 35008341 DOI: 10.3390/cancers14010177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Wang Y, Chen J, Song C, Shi S, Li Z, Feng ST, Luo Y. Optimization of the tumour response threshold in advanced gastroenteropancreatic neuroendocrine carcinomas treated with cisplatin/etoposide combined chemotherapy. Eur J Radiol 2021;147:110119. [PMID: 34979297 DOI: 10.1016/j.ejrad.2021.110119] [Reference Citation Analysis]
42 Xu JX, Wu DH, Ying LW, Hu HG. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification. World J Gastroenterol 2021; 27(47): 8123-8137 [DOI: 10.3748/wjg.v27.i47.8123] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Li S, Niu M, Deng W, Li N, Wei C, Zhang C, Luo S. Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer Manag Res 2021;13:9085-93. [PMID: 34916851 DOI: 10.2147/CMAR.S343572] [Reference Citation Analysis]
44 Singhal S, Patel G, Singh RB, Potdar R. Grade 3 Neuroendocrine Tumor (G3NET): An Unusual Tumor With A Histochemical Surprise. Cureus 2021;13:e19103. [PMID: 34868755 DOI: 10.7759/cureus.19103] [Reference Citation Analysis]
45 Lee H, Nakamoto R, Moore SE, Pantel AR, Eads JR, Aparici CM, Pryma DA. Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Academic Radiology 2021. [DOI: 10.1016/j.acra.2021.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C, Su P, Wang X, Zhan H. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 2021;1876:188637. [PMID: 34678439 DOI: 10.1016/j.bbcan.2021.188637] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Zhou Y, Liu S, Liu C, Yang J, Lin Q, Zheng S, Chen C, Zhou Q, Chen R. Single-cell RNA sequencing reveals spatiotemporal heterogeneity and malignant progression in pancreatic neuroendocrine tumor. Int J Biol Sci 2021;17:3760-75. [PMID: 34671197 DOI: 10.7150/ijbs.61717] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Zhu J, Xiao W, Li Y. Management of Primary Hepatopancreatobiliary and Ampulla Large Cell Neuroendocrine Carcinoma. J Laparoendosc Adv Surg Tech A 2021. [PMID: 34637632 DOI: 10.1089/lap.2021.0482] [Reference Citation Analysis]
50 Sato H, Saito T, Horii H, Kajiura M, Kikuchi N, Takada N, Taguchi K, Yoshida M, Hasegawa M, Taguchi H, Yoshida Y, Ando K, Fujiya M, Omori Y, Hank T, Liss AS, Gala MK, Makita Y, Ono Y, Mizukami Y, Okumura T. Case Report: A Rare Case of Esophagogastric Junctional Squamous Cell Carcinoma After the Successful Treatment of Neuroendocrine Carcinoma: Clonal Tumor Evolution Revealed by Genetic Analysis. Front Genet 2021;12:608324. [PMID: 34616420 DOI: 10.3389/fgene.2021.608324] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Takagi K, Kamada T, Fuse Y, Kai W, Takahashi J, Nakashima K, Nakaseko Y, Suzuki N, Yoshida M, Okada S, Ohdaira H, Suzuki Y. Nivolumab in combination with radiotherapy for metastatic esophageal neuroendocrine carcinoma after esophagectomy: a case report. Surg Case Rep 2021;7:221. [PMID: 34596772 DOI: 10.1186/s40792-021-01307-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Yordanova A, Ahmadzadehfar H. Combination Therapies with PRRT. Pharmaceuticals (Basel) 2021;14:1005. [PMID: 34681229 DOI: 10.3390/ph14101005] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
53 Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel) 2021;13:4872. [PMID: 34638356 DOI: 10.3390/cancers13194872] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Thomas KE, Boudreaux JP, Thiagarajan R, Marsala A, Voros BA, Ramirez RA. A Peptide Meets a Radionuclide to Combat a Rare Tumor. Ochsner J 2021;21:306-11. [PMID: 34566515 DOI: 10.31486/toj.20.0098] [Reference Citation Analysis]
55 Lithgow K, Venkataraman H, Hughes S, Shah H, Kemp-Blake J, Vickrage S, Smith S, Humphries S, Elshafie M, Taniere P, Diaz-Cano S, Dasari BVM, Almond M, Ford S, Ayuk J, Shetty S, Shah T, Geh I. Well-differentiated gastroenteropancreatic G3 NET: findings from a large single centre cohort. Sci Rep 2021;11:17947. [PMID: 34504148 DOI: 10.1038/s41598-021-97247-x] [Reference Citation Analysis]
56 Detjen KM, Otto R, Giesecke Y, Geisler L, Riemer P, Jann H, Grötzinger C, Sers C, Pascher A, Lüdde T, Leser U, Wiedenmann B, Sigal M, Tacke F, Roderburg C, Hammerich L. Elevated Flt3L Predicts Long-Term Survival in Patients with High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2021;13:4463. [PMID: 34503273 DOI: 10.3390/cancers13174463] [Reference Citation Analysis]
57 Chan DL, Ulaner GA, Pattison D, Wyld D, Ladwa R, Kirchner J, Li BT, Lai WV, Pavlakis N, Roach PJ, Bailey DL. Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. J Nucl Med 2021;62:1278-84. [PMID: 33579809 DOI: 10.2967/jnumed.120.257659] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
58 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
59 Nguyen AH, O'Leary MP, De Andrade JP, Ituarte PG, Warner SG, Melstrom LG, Kessler J, Fong Y, Li D, Singh G. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. Am J Surg 2021:S0002-9610(21)00513-4. [PMID: 34474917 DOI: 10.1016/j.amjsurg.2021.08.030] [Reference Citation Analysis]
60 Wang X, Shi YF, Duan JH, Wang C, Tan HY. S-1 plus temozolomide as second-line treatment for neuroendocrine carcinoma of the breast: A case report. World J Clin Cases 2021; 9(24): 7146-7153 [PMID: 34540971 DOI: 10.12998/wjcc.v9.i24.7146] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Abdelmalak R, Lythgoe MP, Evans J, Flynn M, Waters J, Webb A, Pinato DJ, Sharma R. Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. Cancers (Basel) 2021;13:4232. [PMID: 34439386 DOI: 10.3390/cancers13164232] [Reference Citation Analysis]
62 Frizziero M, Durand A, Taboada RG, Zaninotto E, Luchini C, Chakrabarty B, Hervieu V, Claro LCL, Zhou C, Cingarlini S, Milella M, Walter T, Riechelmann RS, Lamarca A, Hubner RA, Mansoor W, Valle JW, McNamara MG. Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant? Cancers (Basel) 2021;13:4152. [PMID: 34439308 DOI: 10.3390/cancers13164152] [Reference Citation Analysis]
63 Scott AT, Howe JR. Management of Small Bowel Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:223-41. [PMID: 32151357 DOI: 10.1016/j.soc.2019.11.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Chandrasekharan C. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:293-316. [PMID: 32151362 DOI: 10.1016/j.soc.2019.11.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am 2020;29:185-208. [PMID: 32151355 DOI: 10.1016/j.soc.2019.11.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
66 Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol 2021;5:74. [PMID: 34354225 DOI: 10.1038/s41698-021-00214-y] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
67 Prantesh J, Dorth J, Asa SL, Mohamed A. Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. J Neuroendocrinol 2021;33:e13005. [PMID: 34342078 DOI: 10.1111/jne.13005] [Reference Citation Analysis]
68 Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. Oncologist 2021. [PMID: 34342086 DOI: 10.1002/onco.13923] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:863-81. [PMID: 32675783 DOI: 10.1097/MPA.0000000000001597] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 41.0] [Reference Citation Analysis]
70 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
71 Holmager P, Langer SW, Federspiel B, Willemoe GL, Garbyal RS, Melchior L, Klose M, Kjaer A, Hansen CP, Andreassen M, Knigge U. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. J Neuroendocrinol 2021;33:e13018. [PMID: 34414612 DOI: 10.1111/jne.13018] [Reference Citation Analysis]
72 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
73 Hayes AR, Chan DLH, Chan BA, Pavlakis N. The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials. J Neuroendocrinol 2021;:e13015. [PMID: 34397130 DOI: 10.1111/jne.13015] [Reference Citation Analysis]
74 Hofland J, Kaltsas G, de Herder WW. Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41. [PMID: 31555796 DOI: 10.1210/endrev/bnz004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 43] [Article Influence: 28.0] [Reference Citation Analysis]
75 Gonzalez RS. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. Surg Pathol Clin 2020;13:377-97. [PMID: 32773190 DOI: 10.1016/j.path.2020.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Kreppel B, Gonzalez-Carmona MA, Feldmann G, Küppers J, Moon ES, Marinova M, Bundschuh RA, Kristiansen G, Essler M, Roesch F, Gaertner FC. Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin 2021. [PMID: 34256394 DOI: 10.1055/a-1521-8604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Lim KH, Opyrchal M, Acharya A, Boice N, Wu N, Gao F, Webster J, Lockhart AC, Waqar SN, Govindan R, Morgensztern D, Picus J, Tan BR, Baggstrom MQ, Maher CA, Wang-Gillam A. Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies. Eur J Cancer 2021;154:102-10. [PMID: 34256279 DOI: 10.1016/j.ejca.2021.06.012] [Reference Citation Analysis]
78 Bardasi C, Spallanzani A, Benatti S, Spada F, Laffi A, Antonuzzo L, Lavacchi D, Marconcini R, Ferrari M, Rimini M, Caputo F, Santini C, Cerma K, Casadei-Gardini A, Andrikou K, Salati M, Bertolini F, Fontana A, Dominici M, Luppi G, Gelsomino F. Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience. Endocrine 2021. [PMID: 34231124 DOI: 10.1007/s12020-021-02813-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Janson ET, Knigge U, Dam G, Federspiel B, Grønbaek H, Stålberg P, Langer SW, Kjaer A, Arola J, Schalin-Jäntti C, Sundin A, Welin S, Thiis-Evensen E, Sorbye H. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2021;60:931-41. [PMID: 33999752 DOI: 10.1080/0284186X.2021.1921262] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
80 Della Torre S, de Nucci G, Lombardi PM, Grandi S, Manes G, Bollina R. Long-term complete response in metastatic poorly-differentiated neuroendocrine rectal carcinoma with a multimodal approach: A case report. World J Clin Oncol 2021; 12(6): 500-506 [PMID: 34189072 DOI: 10.5306/wjco.v12.i6.500] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Wahab A, Rafae A, Mushtaq K, Venkata K, Sarmad R. Lurbinectedin-Induced Tumor Lysis Syndrome in Small Cell Neuroendocrine Cancer of the Cecum: A First-Ever Case Report. Am J Case Rep 2021;22:e932081. [PMID: 34125741 DOI: 10.12659/AJCR.932081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Mollazadegan K, Welin S, Crona J. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. Curr Treat Options Oncol 2021;22:68. [PMID: 34110508 DOI: 10.1007/s11864-021-00866-9] [Reference Citation Analysis]
83 Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT. Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). J Cancer Res Clin Oncol 2021. [PMID: 34110489 DOI: 10.1007/s00432-021-03672-w] [Reference Citation Analysis]
84 Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. Eur J Cancer 2021;152:100-15. [PMID: 34090142 DOI: 10.1016/j.ejca.2021.04.030] [Reference Citation Analysis]
85 Laenkholm IT, Langer SW, Andreassen M, Holmager P, Kjaer A, Klose M, Federspiel BH, Hansen CP, Knigge U. A short report of 50 patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN). Acta Oncol 2021;60:808-12. [PMID: 33779475 DOI: 10.1080/0284186X.2021.1903077] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
86 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
87 Pellat A, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers (Basel) 2021;13:2448. [PMID: 34070035 DOI: 10.3390/cancers13102448] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
88 Zhang H, Shang D. Nonfunctional Pancreatic Neuroendocrine Carcinoma With Isolated Retroperitoneal Metastasis: A Case Report and Literature Review. Pancreas 2020;49:e29-31. [PMID: 32101939 DOI: 10.1097/MPA.0000000000001468] [Reference Citation Analysis]
89 McGarrah PW, Leventakos K, Hobday TJ, Molina JR, Finnes HD, Westin GF, Halfdanarson TR. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma. Pancreas 2020;49:529-33. [PMID: 32282766 DOI: 10.1097/MPA.0000000000001529] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
90 Wang K, Miao Y, Ning H, Guo F, Bian Y, Wang Q, Sun C, Qi X, Qiu F. Acute-onset paraneoplastic cerebellar degeneration secondary to neuroendocrine carcinoma with atypical prognosis: a case report. J Int Med Res 2021;49:300060521992231. [PMID: 33583245 DOI: 10.1177/0300060521992231] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
91 Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Curr Oncol Rep 2021;23:80. [PMID: 33937962 DOI: 10.1007/s11912-021-01071-5] [Reference Citation Analysis]
92 Jeong H, Shin J, Jeong JH, Kim KP, Hong SM, Kim YI, Ryu JS, Ryoo BY, Yoo C. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open 2021;6:100119. [PMID: 33901869 DOI: 10.1016/j.esmoop.2021.100119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Albertelli M, Grillo F, Lo Calzo F, Puliani G, Rainone C, Colao AAL, Faggiano A; NIKE group. Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask. Front Endocrinol (Lausanne) 2021;12:680305. [PMID: 33967966 DOI: 10.3389/fendo.2021.680305] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Apostolidis L, Dal Buono A, Merola E, Jann H, Jäger D, Wiedenmann B, Winkler EC, Pavel M. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers (Basel) 2021;13:1936. [PMID: 33923759 DOI: 10.3390/cancers13081936] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
95 Albertelli M, Dotto A, Nista F, Veresani A, Patti L, Gay S, Sciallero S, Boschetti M, Ferone D. "Present and future of immunotherapy in Neuroendocrine Tumors". Rev Endocr Metab Disord 2021;22:615-36. [PMID: 33851319 DOI: 10.1007/s11154-021-09647-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
96 Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord 2021;22:595-614. [PMID: 33843007 DOI: 10.1007/s11154-021-09638-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
97 Gile JJ, Liu AJ, McGarrah PW, Eiring RA, Hobday TJ, Starr JS, Sonbol MB, Halfdanarson TR. Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: Mayo Clinic Experience. Pancreas 2021;50:500-5. [PMID: 33939660 DOI: 10.1097/MPA.0000000000001794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
98 Miura T, Ohtsuka H, Aoki T, Aoki S, Hata T, Takadate T, Maeda S, Ariake K, Kawaguchi K, Masuda K, Ishida M, Mizuma M, Nakagawa K, Morikawa T, Fujishima F, Kamei T, Sasano H, Unno M. Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification. BMC Surg 2021;21:176. [PMID: 33789657 DOI: 10.1186/s12893-021-01178-3] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
99 La Rosa S. Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms. Endocr Pathol 2021;32:245-57. [PMID: 33786701 DOI: 10.1007/s12022-021-09676-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
100 Pommergaard HC, Nielsen K, Sorbye H, Federspiel B, Tabaksblat EM, Vestermark LW, Janson ET, Hansen CP, Ladekarl M, Garresori H, Hjortland GO, Sundlöv A, Galleberg R, Knigge P, Kjaer A, Langer SW, Knigge U. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms. J Neuroendocrinol 2021;33:e12967. [PMID: 33769624 DOI: 10.1111/jne.12967] [Reference Citation Analysis]
101 Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, Büscheck F, Amin T, Viol F, Fehrle W, Dum D, Höflmayer D, Burandt E, Clauditz TS, Perez D, Izbicki J, Wilczak W, Sauter G, Steurer S, Schrader J. Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocr Pathol 2020;31:182-9. [PMID: 32144630 DOI: 10.1007/s12022-020-09612-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
102 Lee SM, Sung CO. Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas. Sci Rep 2021;11:6203. [PMID: 33737597 DOI: 10.1038/s41598-021-85593-9] [Reference Citation Analysis]
103 Yu S, Hornick JL, Gonzalez RS. An algorithmic approach utilizing CK7, TTF1, beta-catenin, CDX2, and SSTR2A can help differentiate between gastrointestinal and pulmonary neuroendocrine carcinomas. Virchows Arch 2021. [PMID: 33733343 DOI: 10.1007/s00428-021-03085-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
104 Minczeles NS, Hofland J, de Herder WW, Brabander T. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. Curr Oncol Rep 2021;23:46. [PMID: 33721105 DOI: 10.1007/s11912-021-01037-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Feola T, Centello R, Sesti F, Puliani G, Verrico M, Di Vito V, Di Gioia C, Bagni O, Lenzi A, Isidori AM, Giannetta E, Faggiano A. Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review. Cancers (Basel) 2021;13:1247. [PMID: 33809007 DOI: 10.3390/cancers13061247] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
106 Kobayashi N, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Hiroshima Y, Ichikawa Y. Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma. Cancer Sci 2021;112:1936-42. [PMID: 33453146 DOI: 10.1111/cas.14811] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Dijkstra KK, van den Berg JG, Weeber F, van de Haar J, Velds A, Kaing S, Peters DDGC, Eskens FALM, de Groot DA, Tesselaar MET, Voest EE. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma. Front Endocrinol (Lausanne) 2021;12:627819. [PMID: 33776923 DOI: 10.3389/fendo.2021.627819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
108 Al-Fayea T, Alzahrani M, Almaghrabi H, Alghamdi A, Mohammed K. Recurrent Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm in the Gallbladder: A Case Report. Case Rep Oncol 2021;14:411-7. [PMID: 33776736 DOI: 10.1159/000513031] [Reference Citation Analysis]
109 Xie J, Zhao Y, Zhou Y, He Q, Hao H, Qiu X, Zhao G, Xu Y, Xue F, Chen J, Su G, Li P, Zheng CH, Huang CM. Predictive Value of Combined Preoperative Carcinoembryonic Antigen Level and Ki-67 Index in Patients With Gastric Neuroendocrine Carcinoma After Radical Surgery. Front Oncol. 2021;11:533039. [PMID: 33738246 DOI: 10.3389/fonc.2021.533039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
110 Wu W, Chen J, Bai C, Chi Y, Du Y, Feng S, Huo L, Jiang Y, Li J, Lou W, Luo J, Shao C, Shen L, Wang F, Wang L, Wang O, Wang Y, Wu H, Xing X, Xu J, Xue H, Xue L, Yang Y, Yu X, Yuan C, Zhao H, Zhu X, Zhao Y. The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). Journal of Pancreatology 2021;4:1-17. [DOI: 10.1097/jp9.0000000000000064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Thornblade LW, Warner SG, Melstrom L, Ituarte PHG, Chang S, Li D, Fong Y, Singh G. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms? Surgery 2021;169:1417-23. [PMID: 33637345 DOI: 10.1016/j.surg.2021.01.026] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
112 Punekar SR, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker DJ. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. Am J Clin Oncol 2020;43:846-9. [PMID: 32910023 DOI: 10.1097/COC.0000000000000761] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB. Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist 2021;26:383-8. [PMID: 33496040 DOI: 10.1002/onco.13686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
114 Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas 2021;50:130-7. [PMID: 33560090 DOI: 10.1097/MPA.0000000000001745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
115 Lacombe C, De Rycke O, Couvelard A, Turpin A, Cazes A, Hentic O, Gounant V, Zalcman G, Ruszniewski P, Cros J, de Mestier L. Biomarkers of Response to Etoposide-Platinum Chemotherapy in Patients with Grade 3 Neuroendocrine Neoplasms. Cancers (Basel) 2021;13:643. [PMID: 33562726 DOI: 10.3390/cancers13040643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
116 Pulvirenti A, Raj N, Cingarlini S, Pea A, Tang LH, Luchini C, Chou JF, Grego E, Marinova I, Capanu M, Landoni L, Scarpa A, Allen PJ, Klimstra DS, Reidy-Lagunes DL. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms. Pancreas 2021;50:138-46. [PMID: 33565789 DOI: 10.1097/MPA.0000000000001740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
117 Bian Y, Li J, Cao K, Fang X, Jiang H, Ma C, Jin G, Lu J, Wang L. Magnetic resonance imaging radiomic analysis can preoperatively predict G1 and G2/3 grades in patients with NF-pNETs. Abdom Radiol (NY) 2021;46:667-80. [PMID: 32808056 DOI: 10.1007/s00261-020-02706-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
118 Vyas M, Tang LH, Rekhtman N, Klimstra DS. Alterations in Ki67 Labeling Following Treatment of Poorly Differentiated Neuroendocrine Carcinomas: A Potential Diagnostic Pitfall. Am J Surg Pathol 2021;45:25-34. [PMID: 33177340 DOI: 10.1097/PAS.0000000000001602] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
119 Özdirik B, Jann H, Bischoff P, Fehrenbach U, Tacke F, Roderburg C, Wiedenmann B. PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. Medicine (Baltimore) 2021;100:e23835. [PMID: 33429744 DOI: 10.1097/MD.0000000000023835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
120 Magi L, Rinzivillo M, Panzuto F. Tumor Heterogenity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. Endocrines 2021;2:28-36. [DOI: 10.3390/endocrines2010003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Chatani PD, Agarwal SK, Sadowski SM. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2020;11:575620. [PMID: 33537001 DOI: 10.3389/fendo.2020.575620] [Reference Citation Analysis]
122 Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec JY, Volante M, Mete O, Papotti M. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol 2021;32:192-210. [PMID: 33433884 DOI: 10.1007/s12022-020-09660-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
123 Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocr Pathol 2021;32:309-17. [PMID: 33409812 DOI: 10.1007/s12022-020-09657-8] [Reference Citation Analysis]
124 MacFarlane AW 4th, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother 2021;70:1893-906. [PMID: 33398390 DOI: 10.1007/s00262-020-02811-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
125 Gill AJ. Why did they change that? Practical implications of the evolving classification of neuroendocrine tumours of the gastrointestinal tract. Histopathology 2021;78:162-70. [PMID: 33382490 DOI: 10.1111/his.14172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
127 Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020;49:1-33. [PMID: 31856076 DOI: 10.1097/mpa.0000000000001454] [Cited by in Crossref: 117] [Cited by in F6Publishing: 67] [Article Influence: 58.5] [Reference Citation Analysis]
128 Koffas A, Toumpanakis C. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opin Drug Saf 2021;20:321-34. [PMID: 33338383 DOI: 10.1080/14740338.2021.1867097] [Reference Citation Analysis]
129 Lokesh KN, Anand A, Lakshmaiah KC, Babu KG, Lokanatha D, Jacob LA, Babu MCS, Rudresha AH, Rajeev LK, Saldanha SC, Giri GV, Panwar D, Koppaka D, Patidar R. Clinical profile and treatment outcomes of metastatic neuroendocrine carcinoma: A single institution experience. South Asian J Cancer 2018;7:207-9. [PMID: 30112343 DOI: 10.4103/sajc.sajc_176_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
130 Ueberroth BE, Liu AJ, Starr JS, Hobday TJ, Ashman JB, Mishra N, Bekaii-Saab TS, Halfdanarson TR, Sonbol MB. Neuroendocrine Carcinoma of the Anus and Rectum: Patient Characteristics and Treatment Options. Clin Colorectal Cancer 2021;20:e139-49. [PMID: 33551318 DOI: 10.1016/j.clcc.2020.12.001] [Reference Citation Analysis]
131 Ali AS, Langer SW, Federspiel B, Hjortland GO, Grønbæk H, Ladekarl M, Welin S, Weber Vestermark L, Arola J, Osterlund P, Knigge U, Sørbye H, Micke P, Grimelius L, Grönberg M, Tiensuu Janson E. PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS One 2020;15:e0243900. [PMID: 33315908 DOI: 10.1371/journal.pone.0243900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
132 Suga K, Ogawa H, Sohda M, Katayama C, Ozawa N, Osone K, Okada T, Shiraishi T, Katoh R, Sano A, Sakai M, Yokobori T, Shirabe K, Saeki H. A case of colorectal large cell neuroendocrine carcinoma accompanied by disseminated peritoneal leiomyomatosis. Surg Case Rep 2020;6:316. [PMID: 33296060 DOI: 10.1186/s40792-020-01069-4] [Reference Citation Analysis]
133 Chen Z, Huang W, Wei Z. Small-cell neuroendocrine carcinoma of the rectum - a rare tumor type with poor prognosis: A case report and review of literature. WJCC 2020;8:6089-95. [DOI: 10.12998/wjcc.v8.i23.6089] [Reference Citation Analysis]
134 Chen ZZ, Huang W, Wei ZQ. Small-cell neuroendocrine carcinoma of the rectum — a rare tumor type with poor prognosis: A case report and review of literature. World J Clin Cases 2020; 8(23): 6095-6102 [PMID: 33344610 DOI: 10.12998/wjcc.v8.i23.6095] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Zhao Z, Bian Y, Jiang H, Fang X, Li J, Cao K, Ma C, Wang L, Zheng J, Yue X, Zhang H, Wang X, Madabhushi A, Xu J, Jin G, Lu J. CT-Radiomic Approach to Predict G1/2 Nonfunctional Pancreatic Neuroendocrine Tumor. Acad Radiol 2020;27:e272-81. [PMID: 32037260 DOI: 10.1016/j.acra.2020.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
136 Sasaki H, Goto T, Hirao M, Fujimoto Y. Brain metastasis from gallbladder neuroendocrine carcinoma. BMJ Case Rep 2020;13:e238114. [PMID: 33257386 DOI: 10.1136/bcr-2020-238114] [Reference Citation Analysis]
137 Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, Nagtegaal ID, Klimstra DS, Rugge M, Schirmacher P, Lazar AJ, Odze RD, Carneiro F, Fukayama M, Cree IA; WHO Classification of Tumours Editorial Board. Diagnosis of digestive system tumours. Int J Cancer 2021;148:1040-50. [PMID: 32674220 DOI: 10.1002/ijc.33210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
138 Yordanova A, Biersack HJ, Ahmadzadehfar H. Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors. J Clin Med 2020;9:E3679. [PMID: 33207788 DOI: 10.3390/jcm9113679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
139 Woischke C, Jung P, Jung A, Kumbrink J, Eisenlohr S, Auernhammer CJ, Vieth M, Kirchner T, Neumann J. Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity. J Pathol Clin Res 2021;7:75-85. [PMID: 33197299 DOI: 10.1002/cjp2.183] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 La Rosa S, Uccella S. Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 2021;22:527-38. [PMID: 33169199 DOI: 10.1007/s11154-020-09612-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
141 Samsom KG, Levy S, van Veenendaal LM, Roepman P, Kodach LL, Steeghs N, Valk GD, Wouter Dercksen M, Kuhlmann KFD, Verbeek WHM, Meijer GA, Tesselaar MET, van den Berg JG. Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours. Histopathology 2021;78:556-66. [PMID: 32931025 DOI: 10.1111/his.14252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
142 Choi NY, Kim BS, Oh ST, Yook JH, Kim BS. Comparative Outcomes in Patients With Small- and Large-Cell Neuroendocrine Carcinoma (NEC) and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Stomach. Am Surg 2021;87:631-7. [PMID: 33142079 DOI: 10.1177/0003134820950000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
143 Klempner SJ, Hendifar A, Waters KM, Nissen N, Vail E, Tuli R, Mita A. Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. JCO Precision Oncology 2020. [DOI: 10.1200/po.20.00034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
144 Tran CG, Sherman SK, Chandrasekharan C, Howe JR. Surgical Management of Neuroendocrine Tumor Liver Metastases. Surg Oncol Clin N Am 2021;30:39-55. [PMID: 33220808 DOI: 10.1016/j.soc.2020.08.001] [Reference Citation Analysis]
145 Shi H, Chen L, Zhang Q, Lin Y, Jiang C, Yao H, Hou X, Chen M, Lin R, Chen J. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms. Pancreas 2020;49:1378-82. [PMID: 33122528 DOI: 10.1097/MPA.0000000000001693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
146 Yang M, Zeng L, Hou SZ, Ke NW, Tian BL, Liu XB, Xiang B, Zhang Y. Clinical Features and Long-Term Survival of Metastatic Hepatic Neuroendocrine Neoplasms Secondary to Gastroenteropancreatic Site: An Analysis by Applying the Grading Classification. J Oncol 2020;2020:6572398. [PMID: 33014053 DOI: 10.1155/2020/6572398] [Reference Citation Analysis]
147 Yang M, Zeng L, Ke NW, Tan CL, Tian BL, Liu XB, Xiang B, Zhang Y. World Health Organization grading classification for pancreatic neuroendocrine neoplasms: a comprehensive analysis from a large Chinese institution. BMC Cancer 2020;20:906. [PMID: 32962649 DOI: 10.1186/s12885-020-07356-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
148 Kanthan R, Tharmaradinam S, Asif T, Ahmed S, Kanthan SC. Mixed epithelial endocrine neoplasms of the colon and rectum – An evolution over time: A systematic review. World J Gastroenterol 2020; 26(34): 5181-5206 [PMID: 32982118 DOI: 10.3748/wjg.v26.i34.5181] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
149 Zheng H, Zhao Y, He Q, Hao H, Tian Y, Zou B, Jiang L, Qiu X, Zhou Y, Li Z, Xu Y, Zhao G, Xue F, Li S, Fu W, Li Y, Zhou X, Li Y, Zhu Z, Chen J, Xu Z, Cai L, Li E, Li H, Xie J, Zheng C, Lu J, Li P, Huang C. Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma. Gastric Cancer 2021;24:503-14. [PMID: 32915373 DOI: 10.1007/s10120-020-01119-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
150 Andreasi V, Partelli S, Muffatti F, Manzoni MF, Capurso G, Falconi M. Update on gastroenteropancreatic neuroendocrine tumors. Dig Liver Dis. 2021;53:171-182. [PMID: 32912771 DOI: 10.1016/j.dld.2020.08.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Owens R, Gilmore E, Bingham V, Cardwell C, McBride H, McQuaid S, Humphries M, Kelly P. Comparison of different anti-Ki67 antibody clones and hot-spot sizes for assessing proliferative index and grading in pancreatic neuroendocrine tumours using manual and image analysis. Histopathology 2020;77:646-58. [PMID: 32617996 DOI: 10.1111/his.14200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
152 Li B, Li X, Mao R, Liu M, Fu L, Shi L, Zhao S, Fu M. Overexpression of ODF1 in Gastrointestinal Tract Neuroendocrine Neoplasms: a Novel Potential Immunohistochemical Biomarker for Well-differentiated Neuroendocrine Tumors. Endocr Pathol 2021;32:301-8. [PMID: 32869188 DOI: 10.1007/s12022-020-09649-8] [Reference Citation Analysis]
153 Juhlin CC, Falhammar H, Kjellman M, Åhlén J, Welin S, Calissendorff J. Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission. BMC Gastroenterol 2020;20:290. [PMID: 32854635 DOI: 10.1186/s12876-020-01433-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
154 Rindi G, Wiedenmann B. Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine. Nat Rev Endocrinol 2020;16:590-607. [PMID: 32839579 DOI: 10.1038/s41574-020-0391-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
155 Liu M, Popa EC, Finnerty BM, Fahey TJ 3rd, Zarnegar R. Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms. Curr Gastroenterol Rep 2020;22:50. [PMID: 32797314 DOI: 10.1007/s11894-020-00788-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 Rubino M, Scoazec JY, Pisa E, Faron M, Spaggiari L, Hadoux J, Spada F, Planchard D, Cella CA, Leboulleux S, De Marinis F, Ducreux M, Lamartina L, Baudin E, Fazio N. Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. Lung Cancer 2020;148:149-58. [PMID: 32916569 DOI: 10.1016/j.lungcan.2020.08.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
157 Luley K, Gebauer J, Gebauer N, Tharun L, Buchmann I, Barkhausen J, von Bubnoff N, Lindner K, Keck T, Lehnert H, Schmid SM. [Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research]. Internist (Berl). 2020;61:875-890. [PMID: 32676723 DOI: 10.1007/s00108-020-00832-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Cloyd JM, Ejaz A, Konda B, Makary MS, Pawlik TM. Neuroendocrine liver metastases: a contemporary review of treatment strategies.Hepatobiliary Surg Nutr. 2020;9:440-451. [PMID: 32832495 DOI: 10.21037/hbsn.2020.04.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
159 Merola E, Falconi M, Rinke A, Staettner S, Krendl F, Partelli S, Andreasi V, Gress TM, Pascher A, Arsenic R, Doglioni C, Kaemmerer D, Wiedenmann B, Pavel ME. Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. The American Journal of Surgery 2020;220:284-9. [DOI: 10.1016/j.amjsurg.2020.03.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
160 Luong TV, Nisa Z, Watkins J, Hayes AR. Should immunohistochemical expression of mismatch repair (MMR) proteins and microsatellite instability (MSI) analysis be routinely performed for poorly differentiated colorectal neuroendocrine carcinomas? Endocrinol Diabetes Metab Case Rep 2020;2020:EDM200058. [PMID: 32729847 DOI: 10.1530/EDM-20-0058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
161 Spada F, Maisonneuve P, Fumagalli C, Marconcini R, Gelsomino F, Antonuzzo L, Campana D, Puliafito I, Rossi G, Faviana P, Messerini L, Barberis M, Fazio N. Temozolomide alone or in combination with capecitabine in patients with advanced neuroendocrine neoplasms: an Italian multicenter real-world analysis. Endocrine 2021;72:268-78. [PMID: 32700133 DOI: 10.1007/s12020-020-02421-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
162 Bian Y, Jiang H, Ma C, Wang L, Zheng J, Jin G, Lu J. CT-Based Radiomics Score for Distinguishing Between Grade 1 and Grade 2 Nonfunctioning Pancreatic Neuroendocrine Tumors. AJR Am J Roentgenol 2020;215:852-63. [PMID: 32755201 DOI: 10.2214/AJR.19.22123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
163 La Rosa S, Bonzini M, Sciarra A, Asioli S, Maragliano R, Arrigo M, Foschini MP, Righi A, Maletta F, Motolese A, Papotti M, Sessa F, Uccella S. Exploring the Prognostic Role of Ki67 Proliferative Index in Merkel Cell Carcinoma of the Skin: Clinico-Pathologic Analysis of 84 Cases and Review of the Literature. Endocr Pathol 2020;31:392-400. [PMID: 32696301 DOI: 10.1007/s12022-020-09640-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
164 Bongiovanni A, Liverani C, Pusceddu S, Leo S, Di Meglio G, Tamberi S, Santini D, Gelsomino F, Pucci F, Berardi R, Lolli I, Bergamo F, Ricci S, Foca F, Severi S, Ibrahim T; SENECA Study Team Investigators. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol. BMJ Open 2020;10:e034393. [PMID: 32690499 DOI: 10.1136/bmjopen-2019-034393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
165 Ramírez-Rentería C, Ferreira-Hermosillo A, Marrero-Rodríguez D, Taniguchi-Ponciano K, Melgar-Manzanilla V, Mercado M. An Update on Gastroenteropancreatic Neuroendocrine Neoplasms: From Mysteries to Paradigm Shifts. Arch Med Res 2020;51:765-76. [PMID: 32654882 DOI: 10.1016/j.arcmed.2020.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
166 Hirose S, Hasegawa N, Kawai H, Yamaura M, Mizui T, Komatsu Y, Nagase M, Sato M, Hattori J, Endo M, Yamamoto Y, Ishige K, Fukuda K, Hyodo I, Mizokami Y. Mediastinal Neuroendocrine Carcinoma Slowly Growing for 8 Years after Surgical Resection of Esophageal Squamous Cell Carcinoma. Intern Med 2020;59:2505-9. [PMID: 32641665 DOI: 10.2169/internalmedicine.4584-20] [Reference Citation Analysis]
167 Patel N, Barbieri A, Gibson J. Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas.Surg Pathol Clin. 2019;12:1021-1044. [PMID: 31672292 DOI: 10.1016/j.path.2019.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
168 Wu IC, Chu YY, Wang YK, Tsai CL, Lin JC, Kuo CH, Shih HY, Chung CS, Hu ML, Sun WC, Wang JP, Wang HP. Clinicopathological features and outcome of esophageal neuroendocrine tumor: A retrospective multicenter survey by the digestive endoscopy society of Taiwan. J Formos Med Assoc 2021;120:508-14. [PMID: 32600867 DOI: 10.1016/j.jfma.2020.06.024] [Reference Citation Analysis]
169 Bösch F, Belyaev O, Brunner M, Müller-Debus CF, Grützmann R, Keck T, Uhl W, Witzigmann H, Werner J; Olga Radulova-Mauersberger. [Indications for the Surgical Management of Pancreatic Neuroendocrine Neoplasms]. Zentralbl Chir 2020;145:365-73. [PMID: 32599635 DOI: 10.1055/a-1168-7103] [Reference Citation Analysis]
170 Sawayama H, Komohara Y, Hirao H, Sakata K, Takata N, Yoshinaka I, Harada K, Baba H. Nivolumab exerts therapeutic effects against metastatic lesions from early gastric adenocarcinoma with a small proportion of neuroendocrine carcinoma after gastrectomy: a case report. Clin J Gastroenterol 2020;13:759-65. [PMID: 32592148 DOI: 10.1007/s12328-020-01159-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
171 Juškys R, Poškus E, Beiša A, Gumbys L, Jocius D, Meškauskas R, Strupas K. High-grade well-differentiated neuroendocrine tumour of the cecum diagnosed following incisional hernia repair: a case report. Acta Med Litu 2020;27:17-24. [PMID: 32577092 DOI: 10.6001/actamedica.v27i1.4262] [Reference Citation Analysis]
172 Akın Telli T, Esin E, Yalçın Ş. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Balkan Med J 2020;37:281-6. [PMID: 32573179 DOI: 10.4274/balkanmedj.galenos.2020.2020.1.126] [Reference Citation Analysis]
173 Palmieri LJ, Dermine S, Barré A, Dhooge M, Brezault C, Cottereau AS, Coriat R. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms. J Clin Med 2020;9:E1860. [PMID: 32549203 DOI: 10.3390/jcm9061860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Ito M, Hirano Y, Isii T, Kondo H, Wang L, Asari M, Obara N, Yamaguchi S. Grade 3 well-differentiated neuroendocrine tumor of the rectum: a case report. Surg Case Rep 2020;6:130. [PMID: 32533349 DOI: 10.1186/s40792-020-00893-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
175 Pellat A, Coriat R. Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. J Clin Med. 2020;9. [PMID: 32492939 DOI: 10.3390/jcm9061677] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
176 Taskin OC, Clarke CN, Erkan M, Tsai S, Evans DB, Adsay V. Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication. J Gastrointest Oncol 2020;11:548-58. [PMID: 32655934 DOI: 10.21037/jgo.2020.03.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
177 Tirosh A, Kebebew E. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020;11:567-77. [PMID: 32655936 DOI: 10.21037/jgo.2020.03.11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
178 Couronne T, Girot P, Hadoux J, Lecomte T, Durand A, Fine C, Vandevoorde K, Lombard-Bohas C, Walter T. Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma. Endocr Connect 2020;9:498-505. [PMID: 32380470 DOI: 10.1530/EC-20-0192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
179 Pietrantonio F, Morano F, Niger M, Corallo S, Antista M, Raimondi A, Prisciandaro M, Pagani F, Prinzi N, Nichetti F, Randon G, Torchio M, Corti F, Ambrosini M, Palermo F, Palazzo M, Biamonte L, Platania M, Sposito C, Cosimelli M, Mazzaferro V, Pusceddu S, Cremolini C, de Braud F, Di Bartolomeo M. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. Clin Colorectal Cancer 2020;19:156-64. [PMID: 32513593 DOI: 10.1016/j.clcc.2020.05.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
180 Tran CG, Sherman SK, Howe JR. Small Bowel Neuroendocrine Tumors. Curr Probl Surg 2020;57:100823. [PMID: 33234227 DOI: 10.1016/j.cpsurg.2020.100823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 Antelo G, Hierro C, Fernández JP, Baena E, Bugés C, Layos L, Manzano JL, Caro M, Mesia R. Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. Drugs Context 2020;9:2020-2-4. [PMID: 32477420 DOI: 10.7573/dic.2020-2-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
182 Bian Y, Zhao Z, Jiang H, Fang X, Li J, Cao K, Ma C, Guo S, Wang L, Jin G, Lu J, Xu J. Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors. J Magn Reson Imaging. 2020;. [PMID: 32343872 DOI: 10.1002/jmri.27176] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
183 McNamara MG, Frizziero M, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E. Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis. Ther Adv Med Oncol 2020;12:1758835920915299. [PMID: 32426044 DOI: 10.1177/1758835920915299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
184 Zhang P, Li J, Li J, Zhang X, Zhou J, Wang X, Peng Z, Shen L, Lu M. Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study. Cancer 2020;126 Suppl 9:2086-92. [PMID: 32293725 DOI: 10.1002/cncr.32750] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
185 de Mestier L, Lepage C, Baudin E, Coriat R, Courbon F, Couvelard A, Do Cao C, Frampas E, Gaujoux S, Gincul R, Goudet P, Lombard-Bohas C, Poncet G, Smith D, Ruszniewski P, Lecomte T, Bouché O, Walter T, Cadiot G; Thésaurus National de Cancérologie Digestive (TNCD). Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis 2020;52:473-92. [PMID: 32234416 DOI: 10.1016/j.dld.2020.02.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 10.5] [Reference Citation Analysis]
186 Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D, Lee B, Singh G. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. Ann Surg 2019;270:1131-7. [PMID: 29746336 DOI: 10.1097/SLA.0000000000002809] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
187 Basu S, Adnan A. Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies? Nucl Med Commun 2019;40:1086-7. [PMID: 31365493 DOI: 10.1097/MNM.0000000000001072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
188 Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer. 2019;26:227-239. [PMID: 30540557 DOI: 10.1530/erc-18-0424] [Cited by in Crossref: 41] [Cited by in F6Publishing: 61] [Article Influence: 20.5] [Reference Citation Analysis]
189 Goetz TI, Lang EW, Prante O, Maier A, Cordes M, Kuwert T, Ritt P, Schmidkonz C. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. Ann Nucl Med 2020;34:244-53. [PMID: 32114682 DOI: 10.1007/s12149-020-01440-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
190 Deng BY, Yang M, Wen JY, Hou SZ, Chen Y, Tian BL, Liu XB, Zhang Y. Survivals of patients with pancreatic neuroendocrine carcinomas: An in-depth analysis by the American Joint Committee on Cancer 8th tumor-node-metastasis staging manual. Medicine (Baltimore) 2020;99:e18736. [PMID: 32011453 DOI: 10.1097/MD.0000000000018736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
191 Worth PJ, Leal J, Ding Q, Trickey A, Dua MM, Chatzizacharias N, Soonawalla Z, Athanasopoulos P, Toumpanakis C, Hansen P, Parks RW, Connor S, Parker K, Koea J, Srinavasa S, Ielpo B, Vicente Lopez E, Lawrence B, Visser BC; International Pancreatic Neuroendocrine Tumor Study Group. Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions. HPB (Oxford) 2020;22:1359-67. [PMID: 32081540 DOI: 10.1016/j.hpb.2019.12.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Craig Z, Swain J, Batman E, Wadsley J, Reed N, Faluyi O, Cave J, Sharma R, Chau I, Wall L, Lamarca A, Hubner R, Mansoor W, Sarker D, Meyer T, Cairns DA, Howard H, Valle JW, McNamara MG. NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open 2020;10:e034527. [PMID: 32029495 DOI: 10.1136/bmjopen-2019-034527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
193 Thomas K, Voros BA, Meadows-Taylor M, Smeltzer MP, Griffin R, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA. Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers (Basel) 2020;12:E206. [PMID: 31947598 DOI: 10.3390/cancers12010206] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
194 Alifieris CE, Griniatsos J, Delis SG, Nikolaou M, Avgoustou C, Panagiotidis MI, Souferi-chronopoulou E, Trafalis DT. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas. American Journal of Clinical Oncology 2020;43:305-10. [DOI: 10.1097/coc.0000000000000668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
195 Nielsen K, Binderup T, Langer SW, Kjaer A, Knigge P, Grøndahl V, Melchior L, Federspiel B, Knigge U. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. BMC Cancer 2020;20:27. [PMID: 31924180 DOI: 10.1186/s12885-019-6498-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
196 Nagata H, Tsujimoto H, Yaguchi Y, Kouzu K, Itazaki Y, Ishibashi Y, Tsuchiya S, Sugihara T, Ito N, Harada M, Nomura S, Utsumi Y, Shimazaki H, Kishi Y, Ueno H. Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report. Surg Case Rep 2020;6:5. [PMID: 31916037 DOI: 10.1186/s40792-020-0774-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Nikiforchin A, Peng R, Sittig M, Kotiah S. A Rare Case of Metastatic Heterogeneous Poorly Differentiated Neuroendocrine Carcinoma of Ileum: A Case Report and Literature Review. J Med Cases 2020;11:6-11. [PMID: 34434328 DOI: 10.14740/jmc3401] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
199 Matsushima H, Kaibori M, Hatta M, Ishizaki M, Nakatake R, Okumura T, Yoshii K, Todo T. Efficacy of a third-generation oncolytic herpes simplex virus in neuroendocrine tumor xenograft models. Oncotarget 2019;10:7132-41. [PMID: 31903171 DOI: 10.18632/oncotarget.27391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
200 Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you? Hum Pathol 2020;96:8-33. [PMID: 31857137 DOI: 10.1016/j.humpath.2019.12.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
201 Honma Y, Nagashima K, Hirano H, Shoji H, Iwasa S, Takashima A, Okita N, Kato K, Boku N, Murakami N, Inaba K, Ito Y, Itami J, Kanamori J, Oguma J, Daiko H. Clinical outcomes of locally advanced esophageal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer Med. 2020;9:595-604. [PMID: 31794158 DOI: 10.1002/cam4.2708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
202 Perez K, Chan J. Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2019;12:1045-53. [DOI: 10.1016/j.path.2019.08.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
203 Lin Z, Wang H, Zhang Y, Li G, Pi G, Yu X, Chen Y, Jin K, Chen L, Yang S, Zhu Y, Wu G, Chen J, Zhang T. Development and Validation of a Prognostic Nomogram to Guide Decision-Making for High-Grade Digestive Neuroendocrine Neoplasms. Oncologist 2020;25:e659-67. [PMID: 32297441 DOI: 10.1634/theoncologist.2019-0566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
204 Hauser H, Gerson DS, Reidy-Lagunes D, Raj N. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors. Curr Treat Options Oncol. 2019;20:87. [PMID: 31776785 DOI: 10.1007/s11864-019-0690-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
205 Chen X, Wang X, Abadi M, Kumar A. Colorectal Large-Cell Neuroendocrine Carcinoma: Case Report and Literature Review for Potential Novel Therapeutic Options. Clin Colorectal Cancer 2020;19:61-4. [PMID: 31761668 DOI: 10.1016/j.clcc.2019.10.005] [Reference Citation Analysis]
206 Scoville SD, Cloyd JM, Pawlik TM. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opin Pharmacother. 2020;21:183-191. [PMID: 31760823 DOI: 10.1080/14656566.2019.1694003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
207 Treglia G, Goichot B, Giovanella L, Hindié E, Jha A, Pacak K, Taïeb D, Walter T, Imperiale A. Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine 2020;67:9-19. [PMID: 31734779 DOI: 10.1007/s12020-019-02131-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
208 Merola E, Rinke A, Partelli S, Gress TM, Andreasi V, Kollár A, Perren A, Christ E, Panzuto F, Pascher A, Jann H, Arsenic R, Cremer B, Kaemmerer D, Kump P, Lipp RW, Agaimy A, Wiedenmann B, Falconi M, Pavel ME. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms? Ann Surg Oncol 2020;27:1348-55. [PMID: 31720931 DOI: 10.1245/s10434-019-08049-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
209 Lin JX, Weng XF, Xie XS, Lian NZ, Qiu SL, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Yang YH, Liu SJ, Hu M, Lin YK, Huang CM, Zheng CH, Li P, Xie JW. CDK5RAP3 inhibits angiogenesis in gastric neuroendocrine carcinoma by modulating AKT/HIF-1α/VEGFA signaling. Cancer Cell Int 2019;19:282. [PMID: 31728130 DOI: 10.1186/s12935-019-0997-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
210 Frizziero M, Wang X, Chakrabarty B, Childs A, Luong TV, Walter T, Khan MS, Morgan M, Christian A, Elshafie M, Shah T, Minicozzi A, Mansoor W, Meyer T, Lamarca A, Hubner RA, Valle JW, McNamara MG. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World J Gastroenterol 2019; 25(39): 5991-6005 [PMID: 31660035 DOI: 10.3748/wjg.v25.i39.5991] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
211 Bruera G, Giuliani A, Romano L, Chiominto A, Di Sibio A, Mastropietro S, Cosenza P, Ricevuto E, Schietroma M, Carlei F; Oncology Network ASL1 Abruzzo. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice. BMC Cancer 2019;19:960. [PMID: 31619203 DOI: 10.1186/s12885-019-6214-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Bahr K, Zimmer S, Springer E, Fottner C, Becker S, Ernst BP, Matthias C, Künzel J. High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression. ORL J Otorhinolaryngol Relat Spec 2019;81:309-16. [PMID: 31550725 DOI: 10.1159/000502325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
213 Larouche V, Akirov A, Alshehri S, Ezzat S. Management of Small Bowel Neuroendocrine Tumors. Cancers (Basel) 2019;11:E1395. [PMID: 31540509 DOI: 10.3390/cancers11091395] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
214 Inafuku K, Yokose T, Ito H, Eriguchi D, Samejima J, Nagashima T, Nakayama H, Suzuki M, Yamada K, Masuda M. Two cases of lung neuroendocrine carcinoma with carcinoid morphology. Diagn Pathol 2019;14:104. [PMID: 31511024 DOI: 10.1186/s13000-019-0886-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
215 Adant S, Shah GM, Beauregard J. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2020;47:907-21. [DOI: 10.1007/s00259-019-04499-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
216 Mao R, Li K, Cai JQ, Luo S, Turner M, Blazer D 3rd, Zhao H. Adjuvant Chemotherapy Versus Observation Following Resection for Patients With Nonmetastatic Poorly Differentiated Colorectal Neuroendocrine Carcinomas. Ann Surg. 2019;. [PMID: 31478977 DOI: 10.1097/sla.0000000000003562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
217 Kong G, Hicks RJ. Peptide Receptor Radiotherapy: Current Approaches and Future Directions. Curr Treat Options in Oncol 2019;20. [DOI: 10.1007/s11864-019-0677-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
218 Sonbol MB, Halfdanarson TR. Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. Curr Treat Options Oncol. 2019;20:74. [PMID: 31428952 DOI: 10.1007/s11864-019-0670-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
219 Dinter H, Bohnenberger H, Beck J, Bornemann-kolatzki K, Schütz E, Küffer S, Klein L, Franks TJ, Roden A, Emmert A, Hinterthaner M, Marino M, Brcic L, Popper H, Weis C, Pelosi G, Marx A, Ströbel P. Molecular Classification of Neuroendocrine Tumors of the Thymus. Journal of Thoracic Oncology 2019;14:1472-83. [DOI: 10.1016/j.jtho.2019.04.015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
220 Boons G, Vandamme T, Peeters M, Van Camp G, Op de Beeck K. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. Rev Endocr Metab Disord 2019;20:333-51. [DOI: 10.1007/s11154-019-09508-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
221 Yoshimachi S, Ohtsuka H, Aoki T, Miura T, Ariake K, Masuda K, Ishida M, Mizuma M, Hayashi H, Nakagawa K, Morikawa T, Motoi F, Kanno A, Masamune A, Fujishima F, Sasano H, Kamei T, Naitoh T, Unno M. Mixed adenoneuroendocrine carcinoma of the ampulla of Vater: a case report and literature review. Clin J Gastroenterol 2020;13:37-45. [DOI: 10.1007/s12328-019-01009-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
222 Ji Z, Peng Z, Gong J, Zhang X, Li J, Lu M, Lu Z, Shen L. Hyperprogression after immunotherapy in patients with malignant tumors of digestive system. BMC Cancer 2019;19:705. [PMID: 31315610 DOI: 10.1186/s12885-019-5921-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
223 Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms. J Pathol Clin Res 2019;5:217-26. [PMID: 31136102 DOI: 10.1002/cjp2.135] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
224 Nakao Y, Okino T, Yamashita YI, Taki K, Nakagawa S, Matsumoto K, Goto M, Baba H. Case report of aggressive treatments for large-cell neuroendocrine carcinoma of the esophagus. Int J Surg Case Rep 2019;60:291-5. [PMID: 31265990 DOI: 10.1016/j.ijscr.2019.06.056] [Reference Citation Analysis]
225 Alshammari TF, Hakami RA, Alali MN, AlShammari S, Zayed MA, AlSohaibani MO, Bin Traiki T. A Perforated Colonic Neuroendocrine Tumor with Liver Metastasis: A Case Report and Literature Review. Am J Case Rep 2019;20:920-5. [PMID: 31249283 DOI: 10.12659/AJCR.916288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
226 Elkbuli A, Dowd B, McKenney M, Boneva D. Mixed neuroendocrine and squamous cell carcinoma of the colon: A case report and literature review. Int J Surg Case Rep. 2019;60:309-313. [PMID: 31279236 DOI: 10.1016/j.ijscr.2019.06.060] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
227 Batukbhai BDO, De Jesus-Acosta A. The Molecular and Clinical Landscape of Pancreatic Neuroendocrine Tumors. Pancreas 2019;48:9-21. [PMID: 30531241 DOI: 10.1097/MPA.0000000000001189] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
228 Zhang L, Yang Z, Chen Q, Li M, Zhu X, Wan D, Xie H, Zheng S. Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Oncol Lett 2019;18:1585-96. [PMID: 31423226 DOI: 10.3892/ol.2019.10502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
229 Scott AT, Howe JR. Evaluation and Management of Neuroendocrine Tumors of the Pancreas. Surg Clin North Am 2019;99:793-814. [PMID: 31255207 DOI: 10.1016/j.suc.2019.04.014] [Cited by in Crossref: 16] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
230 Ferrata M, Schad A, Zimmer S, Musholt TJ, Bahr K, Kuenzel J, Becker S, Springer E, Roth W, Weber MM, Fottner C. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. Front Oncol 2019;9:343. [PMID: 31134150 DOI: 10.3389/fonc.2019.00343] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 6.7] [Reference Citation Analysis]
231 Krug S, Teupe F, Michl P, Gress TM, Rinke A. Brain metastases in patients with neuroendocrine neoplasms: risk factors and outcome. BMC Cancer 2019;19:362. [PMID: 30991982 DOI: 10.1186/s12885-019-5559-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
232 Hamano Y, Moriwaki T, To K, Watahiki T, Yamada T, Sakashita S, Hyodo I. A Neuroendocrine Tumor of Unknown Primary Origin that Responded to Treatment Based on Tumor Grade Progression. Intern Med 2019;58:1087-91. [PMID: 30568142 DOI: 10.2169/internalmedicine.1809-18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
233 Yang MW, Fu XL, Jiang YS, Chen XJ, Tao LY, Yang JY, Huo YM, Liu W, Zhang JF, Liu PF, Liu Q, Hua R, Zhang ZG, Sun YW, Liu DJ. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas. World J Gastroenterol 2019; 25(14): 1684-1696 [PMID: 31011254 DOI: 10.3748/wjg.v25.i14.1684] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
234 Cho CM. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors. Korean J Gastroenterol 2019;73:124-31. [PMID: 31013555 DOI: 10.4166/kjg.2019.73.3.124] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
235 Feng T, Lv W, Yuan M, Shi Z, Zhong H, Ling S. Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma. World J Surg Oncol 2019;17:54. [PMID: 30898132 DOI: 10.1186/s12957-019-1597-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
236 Yoshida T, Hijioka S, Hosoda W, Ueno M, Furukawa M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Yane K, Tsuchiya Y, Komoto I, Tanaka H, Tsuji A, Hashigo S, Mine T, Kanno A, Murohisa G, Miyabe K, Takagi T, Matayoshi N, Sakaguchi M, Ishii H, Kojima Y, Matsuo K, Yoshitomi H, Nakamori S, Yanagimoto H, Yatabe Y, Furuse J, Mizuno N. Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. Ann Surg Oncol 2019;26:1385-93. [PMID: 30863939 DOI: 10.1245/s10434-019-07252-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
237 Chan DL, Singh S. Current Chemotherapy Use in Neuroendocrine Tumors. Endocrinol Metab Clin North Am 2018;47:603-14. [PMID: 30098718 DOI: 10.1016/j.ecl.2018.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
238 Waseem N, Aparici CM, Kunz PL. Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. J Nucl Med 2019;60:882-91. [PMID: 30850504 DOI: 10.2967/jnumed.118.217851] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
239 Giovannini E, Giovacchini G, Borsò E, Lazzeri P, Riondato M, Leoncini R, Duce V, Ciarmiello A. [ 68 Ga]-Dota Peptide PET/CT in Neuroendocrine Tumors: Main Clinical Applications. CRP 2019;12:11-22. [DOI: 10.2174/1874471012666181212101244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
240 Giannetta E, Guarnotta V, Rota F, de Cicco F, Grillo F, Colao A, Faggiano A; NIKE. A rare rarity: Neuroendocrine tumor of the esophagus. Crit Rev Oncol Hematol 2019;137:92-107. [PMID: 31014519 DOI: 10.1016/j.critrevonc.2019.02.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
241 Golombek T, Henker R, Rehak M, Quäschling U, Lordick F, Knödler M. A Rare Case of Mixed Adenoneuroendocrine Carcinoma (MANEC) of the Gastroesophageal Junction with HER2/neu Overexpression and Distinct Orbital and Optic Nerve Toxicity after Intravenous Administration of Cisplatin. Oncol Res Treat 2019;42:123-7. [PMID: 30799422 DOI: 10.1159/000495218] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
242 Wolf KI, Jha A, van Berkel A, Wild D, Janssen I, Millo CM, Janssen MJR, Gonzales MK, Timmers HJKM, Pacak K. Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE. Nucl Med Mol Imaging 2019;53:223-30. [PMID: 31231443 DOI: 10.1007/s13139-019-00579-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
243 Sahu A, Jefford M, Lai-Kwon J, Thai A, Hicks RJ, Michael M. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. J Oncol 2019;2019:9032753. [PMID: 30915122 DOI: 10.1155/2019/9032753] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
244 Chiba Y. Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome. Clin Trials 2019;16:237-45. [PMID: 30760066 DOI: 10.1177/1740774519828301] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
245 Komaç Ö, Bengi G, Sağol Ö, Akarsu M. C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. World J Gastrointest Oncol 2019; 11(2): 139-152 [PMID: 30788040 DOI: 10.4251/wjgo.v11.i2.139] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
246 Leung HH, Chan AW. Updates of pancreatic neuroendocrine neoplasm in the 2017 World Health Organization classification. Surg Pract 2019;23:42-7. [DOI: 10.1111/1744-1633.12353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Hofving T, Sandblom V, Arvidsson Y, Shubbar E, Altiparmak G, Swanpalmer J, Almobarak B, Elf AK, Johanson V, Elias E, Kristiansson E, Forssell-Aronsson E, Nilsson O. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. Endocr Relat Cancer 2019;26:437-49. [PMID: 30730850 DOI: 10.1530/ERC-18-0509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
248 Fields AC, Lu P, Vierra BM, Hu F, Irani J, Bleday R, Goldberg JE, Nash GM, Melnitchouk N. Survival in Patients with High-Grade Colorectal Neuroendocrine Carcinomas: The Role of Surgery and Chemotherapy. Ann Surg Oncol. 2019;26:1127-1133. [PMID: 30706232 DOI: 10.1245/s10434-019-07203-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
249 Cloyd JM, Konda B, Shah MH, Pawlik TM. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Rev Clin Pharmacol. 2019;12:101-108. [PMID: 30582383 DOI: 10.1080/17512433.2019.1561273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
250 Yang M, Zhang Y, Zeng L, Ke NW, Tan CL, Tian BL, Xiang B, Liu XB. Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems. Eur J Surg Oncol 2019;45:1054-60. [PMID: 30661921 DOI: 10.1016/j.ejso.2019.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
251 Thomas KEH, Voros BA, Boudreaux JP, Thiagarajan R, Woltering EA, Ramirez RA. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. Oncologist. 2019;24:1076-1088. [PMID: 30635447 DOI: 10.1634/theoncologist.2018-0604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
252 Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. Oncotarget 2019;10:17-29. [PMID: 30713600 DOI: 10.18632/oncotarget.26523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
253 Croitoru A, Dinu I, Herlea V, Becheanu G, Grasu M, Lupescu I, Dima SO, Buica F, Dumitrascu T, Lungulescu C, Croitoru VM, Tanase A, Negru SM, Gramaticu IM. LARGE CELL METASTATIC PANCREATIC NEUROENDOCRINE CARCINOMA TREATED WITH SOMATOSTATIN ANALOGUES - CASE REPORT AND LITERATURE REVIEW. Acta Endocrinol (Buchar) 2019;15:390-7. [PMID: 32010361 DOI: 10.4183/aeb.2019.390] [Reference Citation Analysis]
254 Póvoa S, Azevedo D, Marques C, Barroca H, Costa A. Unknown primary large-cell neuroendocrine tumor. Autops Case Rep 2018;8:e2018025. [PMID: 30533401 DOI: 10.4322/acr.2018.025] [Reference Citation Analysis]
255 Guadagno E, Luglio G, Iacobelli A, Borrelli G, Castaldi A, De Rosa G, Del Basso De Caro M. A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of "High"-grade Well-Differentiated Neuroendocrine Neoplasm. Endocr Pathol 2018;29:289-93. [PMID: 29675587 DOI: 10.1007/s12022-018-9528-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
256 González-Flores E, Serrano R, Sevilla I, Viúdez A, Barriuso J, Benavent M, Capdevila J, Jimenez-Fonseca P, López C, Garcia-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). Clin Transl Oncol 2019;21:55-63. [PMID: 30535553 DOI: 10.1007/s12094-018-1980-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
257 Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. Dis Markers 2018;2018:6878409. [PMID: 30627226 DOI: 10.1155/2018/6878409] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
258 Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. Endocr Connect 2018;7:1535-41. [PMID: 30530877 DOI: 10.1530/EC-18-0478] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
259 Lamarca A, Frizziero M, Barriuso J, McNamara MG, Hubner RA, Valle JW. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clin Transl Oncol. 2019;21:950-953. [PMID: 30506132 DOI: 10.1007/s12094-018-1996-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
260 Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-100. [PMID: 30613284 DOI: 10.7150/thno.30357] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
261 Alese OB, Jiang R, Shaib W, Wu C, Akce M, Behera M, El-Rayes BF. High-Grade Gastrointestinal Neuroendocrine Carcinoma Management and Outcomes: A National Cancer Database Study. Oncologist. 2019;24:911-920. [PMID: 30482824 DOI: 10.1634/theoncologist.2018-0382] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
262 Graham C, Chauhan A, Anthony L. Can a High-grade Neuroendocrine Carcinoma be Functional? Am J Med Sci 2019;357:258-62. [PMID: 30638597 DOI: 10.1016/j.amjms.2018.11.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Uccella S, La Rosa S, Volante M, Papotti M. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocr Pathol. 2018;29:150-168. [PMID: 29520563 DOI: 10.1007/s12022-018-9522-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 10.8] [Reference Citation Analysis]
264 Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K. Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. ESMO Open 2018;3:e000443. [PMID: 30425849 DOI: 10.1136/esmoopen-2018-000443] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
265 Lee NJ, Hruban RH, Fishman EK. Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. Abdom Radiol (NY) 2018;43:3025-34. [PMID: 29594467 DOI: 10.1007/s00261-018-1574-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
266 Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma. Int J Cancer 2019;144:1379-90. [PMID: 30144031 DOI: 10.1002/ijc.31828] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
267 Tsuchihashi K, Arita S, Fujiwara M, Iwasaki K, Hirano A, Yoshihiro T, Nio K, Koga Y, Esaki M, Ariyama H, Kusaba H, Moriyama T, Ohuchida K, Nagai E, Nakamura M, Oda Y, Akashi K, Baba E. Metastatic esophageal carcinosarcoma comprising neuroendocrine carcinoma, squamous cell carcinoma, and sarcoma: A case report. Medicine (Baltimore) 2018;97:e12796. [PMID: 30313107 DOI: 10.1097/MD.0000000000012796] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
268 Qiu MJ, Chen YB, Bi NR, Yang SL, He XX, Xiong ZF. Comparative Clinical Analysis of Gastroenteropancreatic Neuroendocrine Carcinomas with Liver Metastasis and Primary Hepatic Neuroendocrine Carcinomas. Dis Markers 2018;2018:9191639. [PMID: 30416612 DOI: 10.1155/2018/9191639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
269 Martin DR, LaBauve E, Pomo JM, Chiu VK, Hanson JA, Gullapalli RR. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression. Pancreas 2018;47:502-10. [PMID: 29521944 DOI: 10.1097/MPA.0000000000001030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
270 Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord 2017;18:381-91. [PMID: 28871510 DOI: 10.1007/s11154-017-9428-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
271 Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer Journal for Clinicians 2018;68:471-87. [DOI: 10.3322/caac.21493] [Cited by in Crossref: 110] [Cited by in F6Publishing: 161] [Article Influence: 27.5] [Reference Citation Analysis]
272 Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors. Clin Transl Gastroenterol 2018;9:196. [PMID: 30297816 DOI: 10.1038/s41424-018-0058-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
273 Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho S, Saunders TA, Jen K, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma. Mod Pathol 2019;32:290-305. [DOI: 10.1038/s41379-018-0131-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
274 Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Sci Rep 2018;8:13166. [PMID: 30177687 DOI: 10.1038/s41598-018-31383-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
275 Imperiale A, Latgé A, Schaff-Wendling F, Goichot B, Kurtz JE, Malouf GG. Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis. Clin Nucl Med 2018;43:701-2. [PMID: 30036245 DOI: 10.1097/RLU.0000000000002231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
276 Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018;31:1770-86. [PMID: 30140036 DOI: 10.1038/s41379-018-0110-y] [Cited by in Crossref: 288] [Cited by in F6Publishing: 365] [Article Influence: 72.0] [Reference Citation Analysis]
277 Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. J Nucl Med 2019;60:377-85. [PMID: 30115686 DOI: 10.2967/jnumed.118.215848] [Cited by in Crossref: 32] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
278 Singh S, Chan DL. Small Bowel Neuroendocrine Tumors: Big Advances in the Land of Small Tumors. J Oncol Pract 2018;14:485-6. [PMID: 30096275 DOI: 10.1200/JOP.18.00392] [Reference Citation Analysis]
279 Singhi AD, Klimstra DS. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases. Histopathology. 2018;72:168-177. [PMID: 29239037 DOI: 10.1111/his.13408] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
280 Imaoka H, Sasaki M, Takahashi H, Hashimoto Y, Ohno I, Mitsunaga S, Watanabe K, Umemoto K, Kimura G, Suzuki Y, Kan M, Ikeda M. Alternate Endpoints for Phase II Trials in Advanced Neuroendocrine Tumors. Oncologist 2019;24:47-53. [PMID: 30072388 DOI: 10.1634/theoncologist.2017-0651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
281 Amair-Pinedo F, Matos I, Saurí T, Hernando J, Capdevila J. The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. Target Oncol 2017;12:757-74. [PMID: 29143176 DOI: 10.1007/s11523-017-0532-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
282 Zhang L, Wan D, Bao L, Chen Q, Xie H, Xu S, Lin S. Neuroendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Medicine (Baltimore) 2018;97:e11487. [PMID: 30024526 DOI: 10.1097/MD.0000000000011487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
283 Kim JJ, Park SS, Lee TG, Lee HC, Lee SJ. Large Cell Neuroendocrine Carcinoma of the Colon With Carcinomatosis Peritonei. Ann Coloproctol. 2018;34:222-225. [PMID: 30048995 DOI: 10.3393/ac.2018.02.27] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
284 Miki M, Kawabe K, Igarashi H, Abe T, Ohishi Y, Hashimoto R, Karashima T, Yamasaki I, Inoue K, Ito T, Ogawa Y. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease. Intern Med 2018;57:2007-11. [PMID: 29491307 DOI: 10.2169/internalmedicine.0416-17] [Reference Citation Analysis]
285 Frilling A, Clift AK. Surgical Approaches to the Management of Neuroendocrine Liver Metastases. Endocrinol Metab Clin North Am 2018;47:627-43. [PMID: 30098720 DOI: 10.1016/j.ecl.2018.04.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
286 Sorbye H, Baudin E, Perren A. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinol Metab Clin North Am. 2018;47:683-698. [PMID: 30098724 DOI: 10.1016/j.ecl.2018.05.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
287 Inzani F, Petrone G, Rindi G. The New World Health Organization Classification for Pancreatic Neuroendocrine Neoplasia. Endocrinol Metab Clin North Am. 2018;47:463-470. [PMID: 30098710 DOI: 10.1016/j.ecl.2018.04.008] [Cited by in Crossref: 71] [Cited by in F6Publishing: 92] [Article Influence: 17.8] [Reference Citation Analysis]
288 Lee YI, Jeon HK, Im JW, Oh SY, Kim KB, Kim B. Primary Gastric Small Cell Carcinoma: A Case Identified as a Large Subepithelial Tumor from Invisible State in 6 Months. Clin Endosc. 2019;52:76-79. [PMID: 29976037 DOI: 10.5946/ce.2018.062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
289 Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM. Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT. AJR Am J Roentgenol 2018;211:267-77. [PMID: 29975116 DOI: 10.2214/AJR.18.19881] [Cited by in Crossref: 37] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
290 Pérez-sánchez E, Hernández-barroso M, Hernández-hernández G, Gambra-michel L, Barrera-gómez M. Carcinoma neuroendocrino rectal: Una neoplasia infrecuente. Revista Colombiana de Cancerología 2018;22:126-9. [DOI: 10.1016/j.rccan.2017.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Zhang Y, Li C, Chen M. Prognostic value of immunohistochemical factors in esophageal small cell carcinoma (ESCC): analysis of clinicopathologic features of 73 patients. J Thorac Dis 2018;10:4023-31. [PMID: 30174845 DOI: 10.21037/jtd.2018.06.26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
292 Watson GA, Ahmed Y, Picardo S, Chew S, Cobbe S, Mahony C, Crotty J, Wallis F, Shelly MJ, Kiely P, Ipadeola OB, Healy V, Osman N, Gupta RK. Unusual Sites of High-Grade Neuroendocrine Carcinomas: A Case Series and Review of the Literature. Am J Case Rep. 2018;19:710-723. [PMID: 29915166 DOI: 10.12659/ajcr.908953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
293 Zatelli MC, Guadagno E, Messina E, Lo Calzo F, Faggiano A, Colao A, _ _. Open issues on G3 neuroendocrine neoplasms: back to the future. Endocrine-Related Cancer 2018;25:R375-84. [DOI: 10.1530/erc-17-0507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
294 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
295 Raj N, Fazio N, Strosberg J. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. American Society of Clinical Oncology Educational Book 2018. [DOI: 10.1200/edbk_200893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
296 Ohmoto A, Suzuki M, Takai E, Rokutan H, Fujiwara Y, Morizane C, Yanagihara K, Shibata T, Yachida S. Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma. Oncotarget 2018;9:21086-99. [PMID: 29765522 DOI: 10.18632/oncotarget.24930] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
297 Bertani E, Ravizza D, Milione M, Massironi S, Grana CM, Zerini D, Piccioli AN, Spinoglio G, Fazio N. Neuroendocrine neoplasms of rectum: A management update. Cancer Treat Rev. 2018;66:45-55. [PMID: 29684743 DOI: 10.1016/j.ctrv.2018.04.003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
298 Hjerpe SJ, Rahim U, Usman MS, Ansari A, Chowdhury W, Lodhi MU, Rahim M. High-grade Non-small Cell Neuroendocrine Carcinoma of the Esophagus. Cureus 2018;10:e2416. [PMID: 29872597 DOI: 10.7759/cureus.2416] [Reference Citation Analysis]
299 Mizuno Y, Kudo A, Akashi T, Akahoshi K, Ogura T, Ogawa K, Ono H, Mitsunori Y, Ban D, Tanaka S, Tateishi U, Tanabe M. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 2018;144:1155-63. [PMID: 29602973 DOI: 10.1007/s00432-018-2636-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
300 Milione M, Maisonneuve P, Pellegrinelli A, Grillo F, Albarello L, Spaggiari P, Vanoli A, Tagliabue G, Pisa E, Messerini L, Centonze G, Inzani F, Scarpa A, Papotti M, Volante M, Sessa F, Fazio N, Pruneri G, Rindi G, Solcia E, La Rosa S, Capella C. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocr Relat Cancer. 2018;25:583-593. [PMID: 29592868 DOI: 10.1530/erc-17-0557] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 9.0] [Reference Citation Analysis]
301 Chan DL, Dixon M, Law CHL, Koujanian S, Beyfuss KA, Singh S, Myrehaug S, Hallet J. Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases. Ann Surg Oncol 2018;25:1768-74. [PMID: 29560571 DOI: 10.1245/s10434-018-6433-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
302 Chan D, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology 2018;107:32-41. [DOI: 10.1159/000488394] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
303 Lorusso M, Inzani F, Castaldi P, Menghi R, Schinzari G, Rindi G, Rufini V. Is 18F-Fluorodeoxyglucose the Tracer of Choice for Functional Imaging of Neuroendocrine Tumors Grade 3? A Case Report. Pancreas 2018;47:e20-2. [PMID: 29521949 DOI: 10.1097/MPA.0000000000001012] [Reference Citation Analysis]
304 Kang J, Ryu JK, Son JH, Lee JW, Choi JH, Lee SH, Kim YT. Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm. J Gastroenterol Hepatol 2018. [PMID: 29514405 DOI: 10.1111/jgh.14139] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
305 Raj N, Valentino E, Capanu M, Tang LH, Basturk O, Untch BR, Allen PJ, Klimstra DS, Reidy-Lagunes D. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated. Pancreas. 2017;46:296-301. [PMID: 27759713 DOI: 10.1097/mpa.0000000000000735] [Cited by in Crossref: 68] [Cited by in F6Publishing: 39] [Article Influence: 17.0] [Reference Citation Analysis]
306 Ali AS, Grönberg M, Langer SW, Ladekarl M, Hjortland GO, Vestermark LW, Österlund P, Welin S, Grønbæk H, Knigge U, Sorbye H, Janson ET. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Med Oncol 2018;35:47. [PMID: 29511910 DOI: 10.1007/s12032-018-1103-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
307 Li J, Lu M, Lu Z, Li Z, Liu Y, Yang L, Li J, Zhang X, Zhou J, Wang X, Gong J, Gao J, Li Y, Shen L. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget 2017;8:25669-78. [PMID: 27788498 DOI: 10.18632/oncotarget.12900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
308 Garske-Román U, Sandström M, Fröss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging 2018;45:970-88. [PMID: 29497803 DOI: 10.1007/s00259-018-3945-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 18.0] [Reference Citation Analysis]
309 Ribeiro MJM, Alonso T, Gajate P, Molina J, Barquin A, Perna C, Grande E. Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. Autops Case Rep 2018;8:e2018005. [PMID: 29515980 DOI: 10.4322/acr.2018.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Arvidsson Y, Rehammar A, Bergström A, Andersson E, Altiparmak G, Swärd C, Wängberg B, Kristiansson E, Nilsson O. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival. Mod Pathol 2018;31:1302-17. [PMID: 29487354 DOI: 10.1038/s41379-018-0010-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
311 Kawasaki K, Fujii M, Sato T. Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. Dis Model Mech 2018;11:dmm029595. [PMID: 29590641 DOI: 10.1242/dmm.029595] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
312 Gray KD, Moore MD, Panjwani S, Elmously A, Afaneh C, Fahey TJ, Zarnegar R. Predicting Survival and Response to Treatment in Gastroesophageal Neuroendocrine Tumors: An Analysis of the National Cancer Database. Ann Surg Oncol 2018;25:1418-24. [DOI: 10.1245/s10434-018-6389-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
313 Kawano S, Miyashima Y, Miyabe Y, Kawai Y, Murata T, Uda M, Inokuchi T, Okada H. A case of small intestinal neuroendocrine carcinoma diagnosed using double-balloon endoscopy with long-term survival. Clin J Gastroenterol. 2018;11:240-244. [PMID: 29450787 DOI: 10.1007/s12328-018-0834-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
314 Walter T, Malka D, Hentic O, Lombard-bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz J, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec J, Lepage C. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41–BEVANEC randomized phase II study. Digestive and Liver Disease 2018;50:195-8. [DOI: 10.1016/j.dld.2017.11.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
315 Nicolini S, Severi S, Ianniello A, Sansovini M, Ambrosetti A, Bongiovanni A, Scarpi E, Di Mauro F, Rossi A, Matteucci F, Paganelli G. Investigation of receptor radionuclide therapy with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. Eur J Nucl Med Mol Imaging 2018;45:923-30. [DOI: 10.1007/s00259-017-3925-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
316 Han X, Xu X, Ma H, Ji Y, Wang D, Kuang T, Wu W, Song B, Li G, Jin G, Lou W. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology. Endocr Connect 2018;7:355-63. [PMID: 29472376 DOI: 10.1530/EC-17-0388] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
317 Dillon JS, Chandrasekharan C. Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. Future Oncol 2018;14:1155-64. [PMID: 29350062 DOI: 10.2217/fon-2017-0340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
318 Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Oncologist 2018;23:422-32. [PMID: 29330208 DOI: 10.1634/theoncologist.2017-0364] [Cited by in Crossref: 29] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
319 Zandee WT, de Herder WW. The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology 2018;106:357-65. [PMID: 29320780 DOI: 10.1159/000486096] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
320 Blesl A, Krones E, Pollheimer MJ, Haybaeck J, Wiesspeiner U, Lipp RW, Kump P. Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology? Case Rep Oncol 2017;10:1121-6. [PMID: 29430237 DOI: 10.1159/000484473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
321 Won YG, Seo KJ, Hyeon J, Shin OR, Chang E, Sun S, Won HS, Ko YH, Na SJ, Lee SL, Ku YM, Lee DS. Gastroenteropancreatic-origin neuroendocrine carcinomas: Three case reports with favorable responses following localized radiotherapy and a review of literature. Medicine (Baltimore) 2017;96:e9009. [PMID: 29245282 DOI: 10.1097/MD.0000000000009009] [Reference Citation Analysis]
322 Chai SM, Brown IS, Kumarasinghe MP. Gastroenteropancreatic neuroendocrine neoplasms: selected pathology review and molecular updates. Histopathology 2018;72:153-67. [DOI: 10.1111/his.13367] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
323 Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol 2018;6:404-15. [PMID: 29229497 DOI: 10.1016/S2213-8587(17)30401-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 24] [Article Influence: 8.2] [Reference Citation Analysis]
324 Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 2018;124:807-15. [PMID: 29211313 DOI: 10.1002/cncr.31124] [Cited by in Crossref: 54] [Cited by in F6Publishing: 75] [Article Influence: 10.8] [Reference Citation Analysis]
325 Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018;59:426-37. [PMID: 29196939 DOI: 10.1007/s12020-017-1482-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
326 Scoazec JY, Couvelard A; Réseau TENpath. [Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future]. Ann Pathol 2017;37:444-56. [PMID: 29169836 DOI: 10.1016/j.annpat.2017.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 6.6] [Reference Citation Analysis]
327 Boyar Cetinkaya R, Aagnes B, Myklebust TÅ, Thiis-Evensen E. Survival in neuroendocrine neoplasms; A report from a large Norwegian population-based study. Int J Cancer 2018;142:1139-47. [PMID: 29082524 DOI: 10.1002/ijc.31137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
328 Cen D, Chen J, Li Z, Zhao J, Cai X. Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis. PLoS One 2017;12:e0187588. [PMID: 29136022 DOI: 10.1371/journal.pone.0187588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
329 Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET. Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS One 2017;12:e0187667. [PMID: 29112960 DOI: 10.1371/journal.pone.0187667] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
330 Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ 2017;189:E398-404. [PMID: 28385820 DOI: 10.1503/cmaj.160771] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
331 Idrees K, Padmanabhan C, Liu E, Guo Y, Gonzalez RS, Berlin J, Dahlman KB, Beauchamp RD, Shi C. Frequent BRAF mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. J Surg Oncol 2018;117:284-9. [PMID: 28940307 DOI: 10.1002/jso.24834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
332 Öberg K. Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visc Med 2017;33:352-6. [PMID: 29177164 DOI: 10.1159/000475831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
333 Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, Hicks RJ. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging 2018;45:262-77. [DOI: 10.1007/s00259-017-3821-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 9.2] [Reference Citation Analysis]
334 Angelousi A, Kaltsas G, Koumarianou A, Weickert MO, Grossman A. Chemotherapy in NETs: When and how. Rev Endocr Metab Disord 2017;18:485-97. [DOI: 10.1007/s11154-017-9432-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
335 de M Rêgo JF, de Medeiros RSS, Braghiroli MI, Galvão B, Neto JEB, Munhoz RR, Guerra J, Nonogaki S, Kimura L, Pfiffer TE, de Castro G Jr, Hoff PM, Filho DR, Costa FP, Riechelmann RP. Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer. Ecancermedicalscience 2017;11:767. [PMID: 28955403 DOI: 10.3332/ecancer.2017.767] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
336 Allison DB, Mccuiston A, Vandenbussche CJ. The presence of neuroendocrine features generates a broad differential diagnosis in the fine-needle aspiration of bone and soft tissue neoplasms. Journal of the American Society of Cytopathology 2017;6:185-93. [DOI: 10.1016/j.jasc.2017.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
337 Galleberg R, Knigge U, Tiensuu Janson E, Vestermark L, Haugvik S, Ladekarl M, Langer S, Grønbæk H, Österlund P, Hjortland G, Assmus J, Tang L, Perren A, Sorbye H. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology 2017;43:1682-9. [DOI: 10.1016/j.ejso.2017.04.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
338 Valente R, Lykoudis P, Tamburrino D, Inama M, Passas I, Toumpanakis C, Luong TV, Davidson B, Imber C, Malagò M, Rahman SH, Shankar A, Sharma D, Caplin M, Fusai G. Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence. Eur J Surg Oncol 2017;43:2119-28. [PMID: 28821361 DOI: 10.1016/j.ejso.2017.07.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
339 Krug S, Gress TM, Michl P, Rinke A. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors. Digestion 2017;96:67-75. [DOI: 10.1159/000477800] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
340 Deng HY, Chen ZH, Wang ZQ, Wang YC, Li EM, Xu LY, Lin YD, Chen LQ. High expression of Ki-67 is an independent favorable prognostic factor for esophageal small cell carcinoma. Oncotarget 2017;8:55298-307. [PMID: 28903420 DOI: 10.18632/oncotarget.19426] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
341 Milione M, Fazio N. G3 GEP NENs category: are basic and clinical investigations well integrated? Endocrine 2018;60:28-30. [DOI: 10.1007/s12020-017-1365-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
342 Faggiano A, Lo Calzo F, Pizza G, Modica R, Colao A. The safety of available treatments options for neuroendocrine tumors. Expert Opin Drug Saf 2017;16:1149-61. [PMID: 28705090 DOI: 10.1080/14740338.2017.1354984] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
343 Quinn AM, Chaturvedi A, Nonaka D. High-grade Neuroendocrine Carcinoma of the Lung With Carcinoid Morphology: A Study of 12 Cases. Am J Surg Pathol 2017;41:263-70. [PMID: 27879513 DOI: 10.1097/PAS.0000000000000767] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
344 Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40:1192-1202. [PMID: 27259015 DOI: 10.1097/pas.0000000000000662] [Cited by in Crossref: 176] [Cited by in F6Publishing: 78] [Article Influence: 35.2] [Reference Citation Analysis]
345 Takemoto YK, Abe T, Amano H, Hanada K, Okazaki A, Minami T, Kobayashi T, Nakahara M, Yonehara S, Ohdan H, Noriyuki T. Mixed adenoneuroendocrine carcinoma derived from the cystic duct: A case report. Int J Surg Case Rep 2017;39:29-33. [PMID: 28793278 DOI: 10.1016/j.ijscr.2017.07.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
346 De Both A, De Man M, Troisi R, Van Vlierberghe H, Hoorens A, Geboes K. Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography: A case report. Oncol Lett 2017;14:547-52. [PMID: 28693204 DOI: 10.3892/ol.2017.6242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
347 Liu IH, Kunz PL. Biologics in gastrointestinal and pancreatic neuroendocrine tumors. J Gastrointest Oncol 2017;8:457-65. [PMID: 28736633 DOI: 10.21037/jgo.2016.12.09] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
348 Kim HK, Ha SY, Lee J, Park SH, Park JO, Lim HY, Kang WK, Park YS, Kim ST. The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs. Oncotarget 2017;8:73974-80. [PMID: 29088761 DOI: 10.18632/oncotarget.18168] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
349 Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017;79:158-65. [PMID: 28501762 DOI: 10.1016/j.ejca.2017.04.009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
350 Kulkarni HR, Singh A, Baum RP. Advances in the Diagnosis of Neuroendocrine Neoplasms. Semin Nucl Med 2016;46:395-404. [PMID: 27553465 DOI: 10.1053/j.semnuclmed.2016.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
351 Chan DL, Clarke SJ, Diakos CI, Roach PJ, Bailey DL, Singh S, Pavlakis N. Prognostic and predictive biomarkers in neuroendocrine tumours. Critical Reviews in Oncology/Hematology 2017;113:268-82. [DOI: 10.1016/j.critrevonc.2017.03.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
352 Girardi DM, Silva ACB, Rêgo JFM, Coudry RA, Riechelmann RP. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review. Cancer Treat Rev 2017;56:28-35. [PMID: 28456055 DOI: 10.1016/j.ctrv.2017.04.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
353 Brieau B, Coriat R. May we challenge the ENETS guidelines in pancreatic neuroendocrine neoplasms? A quiz for French experts. Dig Liver Dis 2017;49:809-19. [PMID: 28377287 DOI: 10.1016/j.dld.2017.03.006] [Reference Citation Analysis]
354 Leoncini E, Boffetta P, Shafir M, Aleksovska K, Boccia S, Rindi G. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms. Endocrine 2017;58:368-79. [PMID: 28303513 DOI: 10.1007/s12020-017-1273-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 8.2] [Reference Citation Analysis]
355 Díaz Del Arco C, Díaz Pérez JÁ, Ortega Medina L, Sastre Valera J, Fernández Aceñero MJ. Reliability of Ki-67 Determination in FNA Samples for Grading Pancreatic Neuroendocrine Tumors. Endocr Pathol 2016;27:276-83. [PMID: 27688080 DOI: 10.1007/s12022-016-9455-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
356 Lee HE, Mounajjed T, Erickson LA, Wu TT. Sporadic Gastric Well-Differentiated Neuroendocrine Tumors Have a Higher Ki-67 Proliferative Index. Endocr Pathol. 2016;27:259-267. [PMID: 27306997 DOI: 10.1007/s12022-016-9443-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
357 Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T, Campana D, Fazio N, Delle Fave G. Everolimus in Pancreatic Neuroendocrine Carcinomas G3. Pancreas 2017;46:302-5. [DOI: 10.1097/mpa.0000000000000762] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 8.4] [Reference Citation Analysis]
358 Lee L, Ito T, Igarashi H, Ueda K, Fujiyama T, Kawabe K, Ogawa Y. Impact of everolimus on Japanese patients with advanced pancreatic neuroendocrine neoplasms. J Hepatobiliary Pancreat Sci 2017;24:95-102. [DOI: 10.1002/jhbp.418] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
359 Xie JW, Lu J, Lin JX, Zheng CH, Li P, Wang JB, Chen QY, Cao LL, Lin M, Tu RH, Huang CM. Different long-term oncologic outcomes after radical surgical resection for neuroendocrine carcinoma and adenocarcinoma of the stomach. Oncotarget 2017;8:57495-504. [PMID: 28915689 DOI: 10.18632/oncotarget.15488] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
360 Rinke A, Gress TM. Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers. Digestion. 2017;95:109-114. [PMID: 28161703 DOI: 10.1159/000454761] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
361 Lamarca A, Walter T, Pavel M, Borbath I, Freis P, Nuñez B, Childs A, Mcnamara MG, Hubner RA, Garcia-carbonero R, Meyer T, Valle JW, Barriuso J. Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. JNCI J Natl Cancer Inst 2017;109:djw277. [DOI: 10.1093/jnci/djw277] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
362 Liu DJ, Fu XL, Liu W, Zheng LY, Zhang JF, Huo YM, Li J, Hua R, Liu Q, Sun YW. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol 2017; 23(3): 516-524 [PMID: 28210088 DOI: 10.3748/wjg.v23.i3.516] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
363 Mertz AT, Ojemuyiwa MA. A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature. Case Rep Oncol 2016;9:847-53. [PMID: 28101034 DOI: 10.1159/000452655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
364 Cidon EU. New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol 2017; 9(1): 4-20 [PMID: 28144395 DOI: 10.4251/wjgo.v9.i1.4] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
365 Ohmoto A, Rokutan H, Yachida S. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future. Int J Mol Sci 2017;18:E143. [PMID: 28098761 DOI: 10.3390/ijms18010143] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
366 Freis P, Graillot E, Rousset P, Hervieu V, Chardon L, Lombard-Bohas C, Walter T. Prognostic factors in neuroendocrine carcinoma: biological markers are more useful than histomorphological markers. Sci Rep. 2017;7:40609. [PMID: 28074897 DOI: 10.1038/srep40609] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
367 Konukiewitz B, Schlitter AM, Jesinghaus M, Pfister D, Steiger K, Segler A, Agaimy A, Sipos B, Zamboni G, Weichert W, Esposito I, Pfarr N, Klöppel G. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20. Mod Pathol 2017;30:587-98. [PMID: 28059098 DOI: 10.1038/modpathol.2016.217] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 17.4] [Reference Citation Analysis]
368 Fabbri A, Cossa M, Sonzogni A, Papotti M, Righi L, Gatti G, Maisonneuve P, Valeri B, Pastorino U, Pelosi G. Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. Virchows Arch 2017;470:153-64. [PMID: 28054150 DOI: 10.1007/s00428-016-2062-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 8.2] [Reference Citation Analysis]
369 Sun J. Pancreatic neuroendocrine tumors. Intractable Rare Dis Res 2017;6:21-8. [PMID: 28357177 DOI: 10.5582/irdr.2017.01007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
370 Haugvik SP, Kaemmerer D, Gaujoux S, Labori KJ, Verbeke CS, Gladhaug IP. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape. Curr Oncol Rep 2016;18:28. [PMID: 26984415 DOI: 10.1007/s11912-016-0518-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
371 Crippa S, Partelli S, Belfiori G, Palucci M, Muffatti F, Adamenko O, Cardinali L, Doglioni C, Zamboni G, Falconi M. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World J Gastroenterol 2016; 22(45): 9944-9953 [PMID: 28018101 DOI: 10.3748/wjg.v22.i45.9944] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
372 Díaz del Arco C, Esteban López-jamar JM, Ortega Medina L, Díaz Pérez JÁ, Fernández Aceñero MJ. Fine-needle aspiration biopsy of pancreatic neuroendocrine tumors: Correlation between Ki-67 index in cytological samples and clinical behavior: GRADING OF PANCREATIC NEUROENDOCRINE TUMORS IN FNA SAMPLES. Diagn Cytopathol 2017;45:29-35. [DOI: 10.1002/dc.23635] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
373 Okada H, Uchida Y, Matsuzaki N, Goto T, Nishimura S, Kurita A, Nishimura T, Yazumi S, Terajima H. A case of neuroendocrine carcinoma in the hepatic hilar lymph nodes concomitant with an adenocarcinoma of the gallbladder. World J Surg Oncol 2016;14:284. [PMID: 27842605 DOI: 10.1186/s12957-016-1039-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
374 Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors). Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer 2016;16:858. [PMID: 27821081 DOI: 10.1186/s12885-016-2901-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
375 Flaum N, Valle JW, Mansoor W, Mcnamara MG. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology 2016;12:2561-78. [DOI: 10.2217/fon.16.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
376 Fazio N, Milione M. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Cancer Treatment Reviews 2016;50:61-7. [DOI: 10.1016/j.ctrv.2016.08.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
377 . UEG Week 2016 Poster Presentations. United European Gastroenterology Journal 2016;4:A157-720. [DOI: 10.1177/2050640616663689] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
378 Pellat A, Wislez M, Svrcek M, Hammel P, Afchain P, André T. Prise en charge thérapeutique des tumeurs neuroendocrines peu différenciées pulmonaires et des carcinomes neuroendocrines digestifs. Bulletin du Cancer 2016;103:880-95. [DOI: 10.1016/j.bulcan.2016.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
379 Deng Y, Chen X, Ye Y, Shi X, Zhu K, Huang L, Zhang S, Ying M, Lin X. Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas. Contemp Oncol (Pozn) 2016;20:311-9. [PMID: 27688729 DOI: 10.5114/wo.2016.61852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
380 Ito T, Hijioka S, Masui T, Kasajima A, Nakamoto Y, Kobayashi N, Komoto I, Hijioka M, Lee L, Igarashi H, Jensen RT, Imamura M. Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol 2017;52:9-18. [PMID: 27539256 DOI: 10.1007/s00535-016-1250-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
381 Kaemmerer D, Träger T, Hoffmeister M, Sipos B, Hommann M, Sänger J, Schulz S, Lupp A. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy. Oncotarget 2015;6:27566-79. [PMID: 26259237 DOI: 10.18632/oncotarget.4491] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
382 Xie JW, Sun YQ, Feng CY, Zheng CH, Li P, Wang JB, Lin JX, Lu J, Chen QY, Cao LL. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42:1464-1470. [PMID: 27570115 DOI: 10.1016/j.ejso.2016.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
383 Tan HY. Subtype classification and management of gastric neuroendocrine neoplasms. Shijie Huaren Xiaohua Zazhi 2016; 24(22): 3329-3336 [DOI: 10.11569/wcjd.v24.i22.3329] [Reference Citation Analysis]
384 Mosquera C, Koutlas NJ, Fitzgerald TL. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance. Eur J Surg Oncol. 2016;42:1471-1477. [PMID: 27528467 DOI: 10.1016/j.ejso.2016.07.137] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
385 Vijayvergia N, Boland PM, Handorf E, Gustafson KS, Gong Y, Cooper HS, Sheriff F, Astsaturov I, Cohen SJ, Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer. 2016;115:564-570. [PMID: 27482646 DOI: 10.1038/bjc.2016.229] [Cited by in Crossref: 50] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
386 Apostolidis L, Bergmann F, Jäger D, Winkler EC. Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma. Cancer Med 2016;5:2261-7. [PMID: 27456539 DOI: 10.1002/cam4.807] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
387 Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol 2016;3:203-19. [PMID: 30338051 DOI: 10.2217/ije-2016-0006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
388 Coriat R, Walter T, Terris B, Couvelard A, Ruszniewski P. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. Oncologist. 2016;21:1191-1199. [PMID: 27401895 DOI: 10.1634/theoncologist.2015-0476] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 11.7] [Reference Citation Analysis]
389 Nishino H, Hatano E, Seo S, Shibuya S, Anazawa T, Iida T, Masui T, Taura K, Haga H, Uemoto S. Histological features of mixed neuroendocrine carcinoma and hepatocellular carcinoma in the liver: a case report and literature review. Clin J Gastroenterol. 2016;9:272-279. [PMID: 27384317 DOI: 10.1007/s12328-016-0669-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
390 Childs A, Kirkwood A, Edeline J, Luong TV, Watkins J, Lamarca A, Alrifai D, Nsiah-sarbeng P, Gillmore R, Mayer A, Thirlwell C, Sarker D, Valle JW, Meyer T. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine-Related Cancer 2016;23:563-70. [DOI: 10.1530/erc-16-0099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
391 Patel D, Chan D, Cehic G, Pavlakis N, Price TJ. Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Rev Endocrinol Metab 2016;11:311-27. [PMID: 30058926 DOI: 10.1080/17446651.2016.1199952] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
392 Wong MH, Chan DL, Lee A, Li BT, Lumba S, Clarke SJ, Samra J, Pavlakis N. Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET). PLoS One 2016;11:e0158140. [PMID: 27362760 DOI: 10.1371/journal.pone.0158140] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
393 Nanno Y, Toyama H, Otani K, Asari S, Goto T, Terai S, Ajiki T, Zen Y, Fukumoto T, Ku Y. Microscopic venous invasion in patients with pancreatic neuroendocrine tumor as a potential predictor of postoperative recurrence. Pancreatology. 2016;16:882-887. [PMID: 27350059 DOI: 10.1016/j.pan.2016.06.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
394 Crippa S, Partelli S, Bassi C, Berardi R, Capelli P, Scarpa A, Zamboni G, Falconi M. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. Surgery. 2016;159:862-871. [PMID: 26602841 DOI: 10.1016/j.surg.2015.09.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
395 Kimura T, Miyamoto H, Fukuya A, Kitamura S, Okamoto K, Kimura M, Muguruma N, Ikemoto T, Shimada M, Yoneda A, Bando Y, Takishita M, Takayama T. Neuroendocrine carcinoma of the pancreas with similar genetic alterations to invasive ductal adenocarcinoma. Clin J Gastroenterol. 2016;9:261-265. [PMID: 27262570 DOI: 10.1007/s12328-016-0655-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
396 Ramirez RA, Beyer DT, Chauhan A, Boudreaux JP, Wang YZ, Woltering EA. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors. Oncologist. 2016;21:671-675. [PMID: 27226359 DOI: 10.1634/theoncologist.2015-0470] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
397 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 6.5] [Reference Citation Analysis]
398 Klimstra DS. Reassessing the grade of gastroenteropancreatic neuroendocrine neoplasms. Endocrine 2016;53:4-6. [DOI: 10.1007/s12020-016-0966-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
399 Merola E, Rinzivillo M, Cicchese N, Capurso G, Panzuto F, Delle Fave G. Digestive neuroendocrine neoplasms: A 2016 overview. Dig Liver Dis. 2016;48:829-835. [PMID: 27212431 DOI: 10.1016/j.dld.2016.04.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
400 Brieau B, Lepère C, Walter T, Lecomte T, Guimbaud R, Manfredi S, Tougeron D, Desseigne F, Lourenco N, Afchain P, El Hajbi F, Terris B, Rougier P, Coriat R. Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues. Medicine (Baltimore) 2015;94:e1864. [PMID: 26496341 DOI: 10.1097/MD.0000000000001864] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
401 Pescatori LC, Festa S, Panzuto F, Pilozzi E, Prosperi D, Rinzivillo M, Pizzichini P, Iaquinto G, Iannicelli E, Mené P, Delle Fave G, Capurso G. A Case of Pancreatic Small Cell Neuroendocrine Carcinoma Associated With SIADH. Pancreas 2016;45:e20-2. [PMID: 27077720 DOI: 10.1097/MPA.0000000000000558] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
402 Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. Cancer Discov 2016;6:594-600. [PMID: 27048246 DOI: 10.1158/2159-8290.CD-15-1192] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
403 Hammond WA, Crozier JA, Nakhleh RE, Mody K. Genomic profiling of high-grade large-cell neuroendocrine carcinoma of the colon. J Gastrointest Oncol 2016;7:E22-4. [PMID: 27034803 DOI: 10.3978/j.issn.2078-6891.2015.090] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
404 Chan JA, Kulke MH. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. Surg Oncol Clin N Am 2016;25:423-37. [PMID: 27013373 DOI: 10.1016/j.soc.2015.11.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
405 Klimstra DS, Beltran H, Lilenbaum R, Bergsland E. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap. Am Soc Clin Oncol Educ Book. 2015;35:92-103. [PMID: 25993147 DOI: 10.14694/EdBook_AM.2015.35.92] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
406 Kadhim MM, Jespersen ML, Pilegaard HK, Nordsmark M, Villadsen GE. Mixed Adenoneuroendocrine Carcinoma Is a Rare but Important Tumour Found in the Oesophagus. Case Rep Gastrointest Med 2016;2016:9542687. [PMID: 26955490 DOI: 10.1155/2016/9542687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
407 Eads JR. Poorly Differentiated Neuroendocrine Tumors. Hematology/Oncology Clinics of North America 2016;30:151-62. [DOI: 10.1016/j.hoc.2015.09.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
408 Khasraw M, Ananda S, Michael M. Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy. Expert Rev Anticancer Ther 2016;16:391-401. [PMID: 26808925 DOI: 10.1586/14737140.2016.1146135] [Reference Citation Analysis]
409 Lamarca A, Elliott E, Barriuso J, Backen A, McNamara MG, Hubner R, Valle JW. Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause? Cancer Treat Rev. 2016;44:26-41. [PMID: 26855376 DOI: 10.1016/j.ctrv.2016.01.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
410 Alba E, Lluch A, Ribelles N, Anton-Torres A, Sanchez-Rovira P, Albanell J, Calvo L, García-Asenjo JA, Palacios J, Chacon JI, Ruiz A, De la Haba-Rodriguez J, Segui-Palmer MA, Cirauqui B, Margeli M, Plazaola A, Barnadas A, Casas M, Caballero R, Carrasco E, Rojo F. High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer. Oncologist 2016;21:150-5. [PMID: 26786263 DOI: 10.1634/theoncologist.2015-0312] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
411 Amin S, Kim MK. Islet Cell Tumors of the Pancreas. Gastroenterol Clin North Am 2016;45:83-100. [PMID: 26895682 DOI: 10.1016/j.gtc.2015.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
412 Khan MS, Kirkwood AA, Tsigani T, Lowe H, Goldstein R, Hartley JA, Caplin ME, Meyer T. Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. Clin Cancer Res 2016;22:79-85. [PMID: 26199388 DOI: 10.1158/1078-0432.CCR-15-1008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
413 Schmitt AM, Blank A, Marinoni I, Komminoth P, Perren A. Histopathology of NET: Current concepts and new developments. Best Practice & Research Clinical Endocrinology & Metabolism 2016;30:33-43. [DOI: 10.1016/j.beem.2016.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
414 La Rosa S, Vanoli A. Republished: gastric neuroendocrine neoplasms and related precursor lesions. Postgrad Med J. 2015;91:163-173. [PMID: 25740317 DOI: 10.1136/postgradmedj-2014-202515rep] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
415 Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016;15:e1-e7. [PMID: 26810202 DOI: 10.1016/j.clcc.2015.12.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
416 Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Grønbæk H, Gladhaug IP, Sorbye H. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Ann Surg Oncol 2016;23:1721-8. [PMID: 26678407 DOI: 10.1245/s10434-015-5013-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 51] [Article Influence: 5.7] [Reference Citation Analysis]
417 Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015;10:e0143822. [PMID: 26630134 DOI: 10.1371/journal.pone.0143822] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
418 Du S, Ni J, Weng L, Ma F, Li S, Wang W, Sang X, Lu X, Zhong S, Mao Y. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors. Medicine (Baltimore) 2015;94:e1429. [PMID: 26313798 DOI: 10.1097/MD.0000000000001429] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
419 Marquez-medina D, Popat S. Systemic therapy for pulmonary carcinoids. Lung Cancer 2015;90:139-47. [DOI: 10.1016/j.lungcan.2015.08.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
420 Klimstra DS. Pathologic Classification of Neuroendocrine Neoplasms. Hematol Oncol Clin North Am. 2016;30:1-19. [PMID: 26614366 DOI: 10.1016/j.hoc.2015.08.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
421 Raj N, Reidy-Lagunes D. Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am. 2016;30:119-133. [PMID: 26614372 DOI: 10.1016/j.hoc.2015.09.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
422 Tang LH, Untch BR, Reidy DL, O'Reilly E, Dhall D, Jih L, Basturk O, Allen PJ, Klimstra DS. Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas. Clin Cancer Res. 2016;22:1011-1017. [PMID: 26482044 DOI: 10.1158/1078-0432.ccr-15-0548] [Cited by in Crossref: 155] [Cited by in F6Publishing: 157] [Article Influence: 22.1] [Reference Citation Analysis]
423 Koo J, Dhall D. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy? Semin Diagn Pathol 2015;32:456-68. [PMID: 26573790 DOI: 10.1053/j.semdp.2015.09.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
424 Tanaka H, Matsusaki S, Baba Y, Isono Y, Kumazawa H, Sase T, Okano H, Saito T, Mukai K, Kaneko H. Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate. Clin J Gastroenterol. 2015;8:414-420. [PMID: 26439620 DOI: 10.1007/s12328-015-0609-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
425 Pea A, Hruban RH, Wood LD. Genetics of pancreatic neuroendocrine tumors: implications for the clinic. Expert Rev Gastroenterol Hepatol. 2015;9:1407-1419. [PMID: 26413978 DOI: 10.1586/17474124.2015.1092383] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
426 Lee L, Igarashi H, Fujimori N, Hijioka M, Kawabe K, Oda Y, Jensen RT, Ito T. Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study. Jpn J Clin Oncol 2015;45:1131-8. [PMID: 26378090 DOI: 10.1093/jjco/hyv143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
427 Sasano H, Satoh F, Nakamura Y. Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma. Endocr Pathol 2014;25:366-70. [PMID: 25252621 DOI: 10.1007/s12022-014-9334-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
428 Nagtegaal ID, Hugen N. The Increasing Relevance of Tumour Histology in Determining Oncological Outcomes in Colorectal Cancer. Curr Colorectal Cancer Rep 2015;11:259-66. [PMID: 26321889 DOI: 10.1007/s11888-015-0280-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
429 Sugimoto M, Takagi T, Hikichi T, Suzuki R, Watanabe K, Nakamura J, Kikuchi H, Konno N, Waragai Y, Asama H, Takasumi M, Watanabe H, Obara K, Ohira H. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading. World J Gastroenterol 2015; 21(26): 8118-8124 [PMID: 26185384 DOI: 10.3748/wjg.v21.i26.8118] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
430 Pusceddu S, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M, Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology 2015;11:1947-59. [DOI: 10.2217/fon.15.86] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
431 Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22:657-664. [PMID: 26113608 DOI: 10.1530/erc-15-0119] [Cited by in Crossref: 183] [Cited by in F6Publishing: 192] [Article Influence: 26.1] [Reference Citation Analysis]
432 Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015;39:683-690. [PMID: 25723112 DOI: 10.1097/pas.0000000000000408] [Cited by in Crossref: 263] [Cited by in F6Publishing: 120] [Article Influence: 37.6] [Reference Citation Analysis]
433 Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014;15:365-379. [PMID: 25092520 DOI: 10.1007/s11864-014-0294-4] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 7.6] [Reference Citation Analysis]
434 Villa Grajeda MG, Ronquillo Carreón CA, Morán Mendoza ADJ, Dip Borunda AK. Tumores neuroendocrinos: experiencia de 6 años en un centro de tercer nivel. Gaceta Mexicana de Oncología 2015;14:141-9. [DOI: 10.1016/j.gamo.2015.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
435 Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol. 2015;33:1855-1863. [PMID: 25918282 DOI: 10.1200/jco.2014.60.2532] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 12.6] [Reference Citation Analysis]
436 Shafqat H, Ali S, Salhab M, Olszewski AJ. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015;58:294-303. [PMID: 25664707 DOI: 10.1097/dcr.0000000000000298] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
437 Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) 2015;5:119-76. [PMID: 26854147 DOI: 10.3390/diagnostics5020119] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
438 Briest F, Grabowski P. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Cancer Treat Rev 2015;41:423-30. [PMID: 25837868 DOI: 10.1016/j.ctrv.2015.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
439 Maschmeyer G, Mügge LO, Kämpfe D, Kreibich U, Wilhelm S, Aßmann M, Schwarz M, Kahl C, Köhler S, Grobe N, Niederwieser D. A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012. J Cancer Res Clin Oncol 2015;141:1639-44. [PMID: 25773126 DOI: 10.1007/s00432-015-1954-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
440 Ikeda M, Okuyama H, Takahashi H, Ohno I, Shimizu S, Mitsunaga S, Kondo S, Morizane C, Ueno H, Okusaka T. Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. J Hepatobiliary Pancreat Sci 2015;22:623-7. [PMID: 25755102 DOI: 10.1002/jhbp.228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
441 Narayanan S, Kunz PL. Beyond biologics: is there a role for systemic cytotoxic chemotherapy in neuroendocrine tumors? International Journal of Endocrine Oncology 2015;2:13-20. [DOI: 10.2217/ije.14.37] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
442 La Rosa S, Sessa F. High-grade poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: from morphology to proliferation and back. Endocr Pathol. 2014;25:193-198. [PMID: 24715269 DOI: 10.1007/s12022-014-9316-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
443 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192. [PMID: 24699927 DOI: 10.1007/s12022-014-9313-z] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 14.3] [Reference Citation Analysis]
444 Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas. Am J Surg Pathol. 2015;39:13-24. [PMID: 25353284 DOI: 10.1097/pas.0000000000000341] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 5.9] [Reference Citation Analysis]
445 Hotchen AJ, Naidoo K, Lanzon-Miller S. Multiple, persistent gastropancreato-neuroendocrine tumours accompanying sigmoid bowel adenocarcinoma: A rare case report. Ann Med Surg (Lond) 2014;3:51-4. [PMID: 25568786 DOI: 10.1016/j.amsu.2014.06.002] [Reference Citation Analysis]
446 Reid MD, Balci S, Saka B, Adsay NV. Neuroendocrine tumors of the pancreas: current concepts and controversies. Endocr Pathol. 2014;25:65-79. [PMID: 24430597 DOI: 10.1007/s12022-013-9295-2] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 10.5] [Reference Citation Analysis]
447 Sahnane N, Furlan D, Monti M, Romualdi C, Vanoli A, Vicari E, Solcia E, Capella C, Sessa F, La Rosa S. Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 2015;22:35-45. [PMID: 25465415 DOI: 10.1530/erc-14-0410] [Cited by in Crossref: 71] [Cited by in F6Publishing: 76] [Article Influence: 8.9] [Reference Citation Analysis]
448 Panzuto F, Merola E, Rinzivillo M, Partelli S, Campana D, Iannicelli E, Pilozzi E, Mercantini P, Rossi M, Capurso G, Scarpa A, Cascinu S, Tomassetti P, Falconi M, Delle Fave G. Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome. Pancreas 2014;43:212-8. [PMID: 24518498 DOI: 10.1097/MPA.0000000000000032] [Cited by in Crossref: 38] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
449 Janson ET, Sorbye H, Welin S, Federspiel B, Grønbæk H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jäntti C, Sundin A, Sundlöv A, Thiis-Evensen E, Knigge U. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol 2014;53:1284-97. [PMID: 25140861 DOI: 10.3109/0284186X.2014.941999] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 10.4] [Reference Citation Analysis]
450 Shi C, Klimstra DS. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics. Semin Diagn Pathol 2014;31:498-511. [PMID: 25441311 DOI: 10.1053/j.semdp.2014.08.008] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
451 Kashyap R, Hofman MS, Michael M, Kong G, Akhurst T, Eu P, Zannino D, Hicks RJ. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2015;42:176-85. [PMID: 25209134 DOI: 10.1007/s00259-014-2906-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 6.9] [Reference Citation Analysis]
452 Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 2014;105:1176-1181. [PMID: 24975505 DOI: 10.1111/cas.12473] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 14.0] [Reference Citation Analysis]
453 Hijioka S, Hosoda W, Mizuno N, Hara K, Imaoka H, Bhatia V, Mekky MA, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutumi H, Fujiyoshi T, Sato T, Hieda N, Yoshida T, Okuno N, Shimizu Y, Yatabe Y, Niwa Y, Yamao K. Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas? J Gastroenterol. 2015;50:564-572. [PMID: 25142799 DOI: 10.1007/s00535-014-0987-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 6.9] [Reference Citation Analysis]
454 Panzuto F, Rinzivillo M, Fazio N, de Braud F, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Cartenì G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist 2014;19:966-74. [PMID: 25117065 DOI: 10.1634/theoncologist.2014-0037] [Cited by in Crossref: 52] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]
455 Rindi G, Inzani F. Grading neuroendocrine tumors: are we there? International Journal of Endocrine Oncology 2014;1:27-30. [DOI: 10.2217/ije.13.5] [Reference Citation Analysis]
456 Olsen IH, Knigge U, Federspiel B, Hansen CP, Skov A, Kjær A, Langer SW. Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. J Cancer 2014;5:628-32. [PMID: 25157273 DOI: 10.7150/jca.9409] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
457 La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014;67:938-948. [PMID: 25053544 DOI: 10.1136/jclinpath-2014-202515] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
458 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
459 Basturk O, Tang L, Hruban RH, Adsay V, Yang Z, Krasinskas AM, Vakiani E, La Rosa S, Jang KT, Frankel WL, Liu X, Zhang L, Giordano TJ, Bellizzi AM, Chen JH, Shi C, Allen P, Reidy DL, Wolfgang CL, Saka B, Rezaee N, Deshpande V, Klimstra DS. Poorly differentiated neuroendocrine carcinomas of the pancreas: a clinicopathologic analysis of 44 cases. Am J Surg Pathol. 2014;38:437-447. [PMID: 24503751 DOI: 10.1097/pas.0000000000000169] [Cited by in Crossref: 134] [Cited by in F6Publishing: 57] [Article Influence: 16.8] [Reference Citation Analysis]
460 Wang SM, Ye M, Ni SM. Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review. BMC Cancer 2014;14:305. [PMID: 24884973 DOI: 10.1186/1471-2407-14-305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
461 Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014;120:2814-2823. [PMID: 24771552 DOI: 10.1002/cncr.28721] [Cited by in Crossref: 174] [Cited by in F6Publishing: 178] [Article Influence: 21.8] [Reference Citation Analysis]
462 Smith JD, Reidy DL, Goodman KA, Shia J, Nash GM. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21:2956-2962. [PMID: 24763982 DOI: 10.1245/s10434-014-3725-3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 8.8] [Reference Citation Analysis]
463 Volante M, Birocco N, Gatti G, Duregon E, Lorizzo K, Fazio N, Scagliotti GV, Papotti M. Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Human Pathology 2014;45:665-73. [DOI: 10.1016/j.humpath.2013.03.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
464 Limani P, Tschuor C, Gort L, Balmer B, Gu A, Ceresa C, Raptis DA, Lesurtel M, Puhan M, Breitenstein S. Nonsurgical Strategies in Patients With NET Liver Metastases: A Protocol of Four Systematic Reviews. JMIR Res Protoc 2014;3:e9. [PMID: 24610518 DOI: 10.2196/resprot.2893] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
465 Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours: . Current Opinion in Endocrinology & Diabetes and Obesity 2014;21:22-7. [DOI: 10.1097/med.0000000000000033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
466 Solomou S, Khan R, Propper D, Berney D, Druce M. A case of insulin and ACTH co-secretion by a neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep 2014;2014:130082. [PMID: 24683485 DOI: 10.1530/EDM-13-0082] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
467 Yang Z, Tang LH, Klimstra DS. Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues. Semin Diagn Pathol. 2013;30:186-196. [PMID: 24144288 DOI: 10.1053/j.semdp.2013.06.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
468 Ramella Munhoz R, de Mendonça Rego JF, de Celis Ferrari AR, Ignez Braghiroli M, Mendonça Bariani G, Marcelo Hoff P, Perego Costa F, Eduardo Flesch Pfiffer T, Riechelmann R. Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare Tumors 2013;5:e39. [PMID: 24179651 DOI: 10.4081/rt.2013.e39] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
469 Strosberg J. Evolving Treatment Strategies for Management of Carcinoid Tumors. Curr Treat Options in Oncol 2013;14:374-88. [DOI: 10.1007/s11864-013-0246-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
470 Nagaraju GP, Zafar SF, El-Rayes BF. Pleiotropic effects of genistein in metabolic, inflammatory, and malignant diseases. Nutr Rev. 2013;71:562-572. [PMID: 23865800 DOI: 10.1111/nure.12044] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
471 Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:819-31. [PMID: 23582921 DOI: 10.1016/j.bpg.2012.12.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
472 Bergsland EK. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors. Semin Oncol 2013;40:1-3. [PMID: 23391108 DOI: 10.1053/j.seminoncol.2012.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
473 Bergsland EK. The Evolving Landscape of Neuroendocrine Tumors. Seminars in Oncology 2013;40:4-22. [DOI: 10.1053/j.seminoncol.2012.11.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
474 Hammel P, Hentic O, Neuzillet C, Faivre S, Raymond E, Ruszniewski P. New treatment options with cytotoxic agents in neuroendocrine tumours. Targ Oncol 2012;7:169-72. [DOI: 10.1007/s11523-012-0228-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]